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Parkinson’s disease is the second most common neurodegenerative disorder. Many 
clues about potential causes for PD have been gained from studies of disease-associated 
genetic mutations identified in familial PD cases. In 2011, missense mutations 
(p.Arg1502His and p.Ala502Val) of EIF4G1 gene were reported to be associated with 
autosomal dominant familial PD. EIF4G1 encodes a protein named eIF4G1 (eukaryotic 
translation initiation factor 4, gamma 1), which is a scaffold component in a mRNA 
translation initiation complex that performs a key role in both cap-dependent and cap-
independent translation initiation. However, following sequencing studies indicated 
mutations of EIF4G1 seemed to be rare, and standard genetic approaches had not been able 
to confirm the mutations are causal. 
To study the pathological roles of EIF4G1 mutations in vivo, we generated the 
Drosophila model expressing human eIF4G1 in dopaminergic neurons by crossing newly 
generated UAS lines with a dopaminergic neuron specific GAL4 driver line. We tried three 
different approaches to obtain the UAS lines with relatively equal and robust transgene 
expression. Through characterization, we found the RH-EIF4G1 and AV-EIF4G1 
transgenic flies had early mortality, late-onset locomotion impairment, and age-related 
dopaminergic neurodegeneration, while the WT-EIF4G1 flies performed the same as the 
non-transgenic wild-type flies. These data suggested a causal link between EIF4G1 
mutations and PD-like phenotypes in Drosophila model. 
To understand if and how the mutations alter the function of eIF4G1 in vitro, we 
generated EIF4G1 mutation knock-in SHSY5Y cell lines, a human neuroblastoma cell line, 
using CRISPR/Cas9 technology. We found global protein translation repression in mutant 
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cells via 35S-Met/Cys metabolic labeling, and consistent results were seen in mutation 
bearing transgenic flies. We found cap-dependent translation was slightly decreased in RH 
knock-in cells, but cap-independent translation was not affected. Whereas in AV knock-in 
cells, both cap-dependent and cap-independent translation were prominently decreased.  
Overall, we demonstrated that EIF4G1 mutations result in PD phenotypes in 
transgenic flies. Protein synthesis is decreased in mutation knock-in cells. These suggest 
that downregulation of mRNA translation may play a role in neurodegeneration. Further 
studies identifying the specific mRNAs affected by EIF4G1 mutations will lead us to 
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Pathology of Parkinson’s disease 
 
Parkinson’s disease (PD) was first described by James Parkinson in his classic 
monograph “Essay on the Shaking Palsy” in 1817 (Parkinson 1817). It is the second-most 
common neurodegenerative disorder with a prevalence of approximately 1% of the 
population at the age of 65 and rising to 5% of those at the age of 85 (Lang and Lozano 
1998, Lang and Lozano 1998). The cardinal clinical motor symptoms including resting 
tremor (shaking occurs when the limb is not in use), bradykinesia (a slowing of physical 
movement), rigidity, and postural instability (Fahn 2003). In addition, non-motor 
symptoms including loss of sense of smell, REM sleep-behavior disorder, constipation, 
mood and behavioral problems, and cognitive impairment are also documented (Chaudhuri, 
Healy et al. 2006). Some non-motor symptoms such as hyposmia, sleep disorders, and 
constipation precede the motor symptoms by several years. Other non-motor symptoms 
such as cognitive impairment appear in the late stage of disease progression (Chaudhuri, 
Healy et al. 2006). The symptoms are unique to each patient, and the progression varies 
from person to person.  
The motor symptoms of the disease are attributable to the progressive and selective 
loss of dopaminergic (DAergic) neurons in substantia nigra pars compacta (Braak, Del 
Tredici et al. 2003). Dopamine, the neurotransmitter mainly produced in substantial nigra 
(SNpc), plays a crucial role in movement control. Loss of dopamine results in abnormal 
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nerve-firing patterns that cause impaired movement (Obeso, Rodriguez-Oroz et al. 2008). 
While the loss of dopamine neurons accounts for the motor dysfunction, recent studies 
have shown that other brain systems are also damaged, including brain regions that regulate 
other neurotransmitters such as serotonin, norepinephrine, and acetylcholine (Barone 
2010). The dysregulations of these neurotransmitters are implicated to account for the non-
motor symptoms (Barone 2010). 
The histopathological hallmarks of PD include the presence of intracellular protein 
inclusions, termed Lewy bodies (LBs), which are predominantly composed of a protein 
named alpha-synuclein (-Syn) (Spillantini, Schmidt et al. 1997, Spillantini, Crowther et 
al. 1998, Spillantini, Crowther et al. 1998). The buildup of abnormal and misfolded -Syn 
forms aggregates or collections, that further accumulate to form protein threads called 
fibrils, the building blocks of Lewy bodies (Wakabayashi, Tanji et al. 2007). Several recent 
studies suggested that -Syn may self-propagate from cell to cell, contributing to the 
progression of PD (Recasens and Dehay 2014).  
Currently, there is no cure for the disease, and the available treatments can only 
relieve the symptoms by supplementing dopamine transmission or slowing down the 
degradation of dopamine (Fahn 2003). Though the drugs are effective during the early 
stages of the disease, over time patients manifest declined responsiveness to the treatment 
and suffer the severe side effects of these drugs (Fahn 2003). To develop the therapeutics 
that could halt the progression or even cure the devastating disease, a better understanding 




Genetics of Parkinson’s Disease  
 
PD had been considered as a typical sporadic disorder until the last two decades. 
The identification of an increasing number of single genetic loci responsible for inherited 
PD with Mendelian pattern has drawn more and more attention into familial PD cases 
(Moore, West et al. 2005, Martin, Dawson et al. 2011). Approximately 15-25% of all PD 
cases have a family history, and 30% of those familial cases and 3%-5% of sporadic PD 
cases can be attributed to single mutation of one of several specific genes. Thus far, the 
genetic mutations of the following five genes have been proved to link to PD pathogenesis 
conclusively. These are: autosomal dominant -Syn and the leucine-rich repeat kinase 2 
(LRRK2); autosomal recessive PD genes parkin, DJ-1, PTEN-induced putative kinase 1 
(PINK1), and ATP13A2 (Table 1) (Golbe, Di Iorio et al. 1990, Polymeropoulos, Lavedan 
et al. 1997, Kitada, Asakawa et al. 1998, Kruger, Kuhn et al. 1998, Abbas, Lucking et al. 
1999, Spira, Sharpe et al. 2001, Bonifati, Rizzu et al. 2003, Singleton, Farrer et al. 2003, 
Chartier-Harlin, Kachergus et al. 2004, Hatano, Li et al. 2004, Zarranz, Alegre et al. 2004, 
Goldwurm, Di Fonzo et al. 2005, Kachergus, Mata et al. 2005, Mata, Taylor et al. 2005, 
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Monogenic PD and sporadic PD share many features including selective 
degeneration of DAergic neurons in the SNpc and Lewy body inclusions, suggesting that 
there may be overlapping signaling pathways that contribute to the pathogenesis of both 
forms of PD (Huang, Cheung et al. 2004, Dawson, Ko et al. 2010). Studies of PD-
associated genetic mutations have brought better understanding into the potential 
pathogenic pathways of PD. For example, A53T mutation of -Syn preferentially promotes 
the formation of -Syn oligomers, which indicates that oligomeric -Syn may be the 
primary toxic species in PD pathogenesis (Conway, Lee et al. 2000). Autosomal recessive 
mutations of parkin, an E3 ubiquitin ligase, are the most common cause of early-onset PD 
(Dawson and Dawson 2010). The majority of the known parkin mutations impact its E3 
ligase activity, screening for the parkin substrates that accumulated in the brains of PD 
patients identified PARIS and its function as transcriptional repressor of peroxisome 
proliferator-activated receptor gamma (PPAR) coactivator-1α (PGC-1), the master 
regulator of mitochondria biogenesis (Shin, Ko et al. 2011). The studies of the parkin-
PARIS-PGC-1pathway have linked pathogenesis of PD to mitochondrial biogenesis. So, 
identification of new PD-causing gene defects and the pathways affected by these genes 
will provide important insight into PD pathogenesis.  
Identification of EIF4G1 variants as PD-associated mutations 
 
Mutations of the EIF4G1 gene were reported associated with autosomal dominant 
familial PD in 2011 (Chartier-Harlin, Dachsel et al. 2011). EIF4G1 encodes a protein 
named eIF4G1 (eukaryotic translation initiation factor 4, gamma 1), one of the three 
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paralogs of eIF4G (Yan and Rhoads 1995, Coldwell, Sack et al. 2012). eIF4G is a scaffold 
component in a mRNA translation initiation complex (Sonenberg, Morgan et al. 1978), 
performing a key role in both cap-dependent and cap-independent translation initiation 
(Jackson, Hellen et al. 2010). Together with PABP and eIF4E, eIF4G circularizes the 
mRNA to stabilize it, and to promote initiation (Gallie 1991). In conventional cap-
dependent translation, eIF4G functions as a molecular bridge. Working with eIF3, eIF4G 
assists the 43S pre-initiation complex loading to the mRNA (Andreou and Klostermeier 
2013, Marchione, Leibovitch et al. 2013). In cap-independent translation initiation, eIF4G 
binds with eIF4A to form a sub-complex, and thereby initiates translation by recruiting 43S 
complex onto internal ribosome entry site (IRES) without the cap-binding eIF4F complex 
(Pelletier and Sonenberg 1988, Ali, McKendrick et al. 2001, Svitkin, Herdy et al. 2005). It 
has been suggested that concentration of eIF4G is a key switch regulating cap-dependent 
and cap-independent translation (Lomakin, Hellen et al. 2000). 
The missense mutation c.3614G>A (p.R1205H) was initially identified in a 
genome-wide linkage analysis of a large French family with autosomal dominant 
Parkinsonism, and the same mutation was also found in another seven small families 
(Chartier-Harlin, Dachsel et al. 2011). In a subsequent screening for novel PD-associated 
EIF4G1 variants, additional 4 variants, c.1505C>T (p.Ala502Val), c.2056G>T 
(p.Gly686Cys), c.3490A>C (p.Ser1164Arg), and c.3589C>T (p.Arg1197Trp), were 
identified in PD cases but not in control subjects (Chartier-Harlin, Dachsel et al. 2011). 
The A502V mutation was the most frequent substitution identified in the study, and also 
suggested from an ancestral founder in the haplotype analysis (Chartier-Harlin, Dachsel et 
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al. 2011). The subsequent neuropathological study showed that patients carrying one or 
double of these EIF4G1 variants manifested clinical features of dementia with Lewy bodies 
(Fujioka, Sundal et al. 2013).  
After the first report of EIF4G1 mutations, other groups performed screens for 
additional EIF4G1 variants. The follow-up studies validated the suggested linkage between 
PD and EIF4G1 mutations, however, several studies also found the initial mutants, 
R1205H and A502V, in their control cohorts, so the exact PD-linked mutation sites are still 
controversial. Tucci et al. identified c.1456C > T (p.Pro486Ser) in two PD individuals out 
of 150 African familial PD cases, but also detected A502V variant in two controls out of 
3500 European-American samples (Tucci, Charlesworth et al. 2012). Also, Schulte et al. 
identified seven novel nonsynonymous variants in six patients with classic PD phenotype 
in their 376 Central European PD cases, including p.Pro16Leu, p.Pro71Ser, p.Thr318Ile, 
p.Val541Gly, p.Ala550Pro, p.Gly698Ala and p.Ala717Pro as well as p.Pro486Ser (Schulte, 
Mollenhauer et al. 2012). Then they assessed the frequency of novel and previously 
reported variants in 975 familial and sporadic PD cases from Austria, Germany, and 
Hungary and 1014 general controls. p.Pro16Leu, p.Thr318Ile, p.Val541Gly, and 
p.Gly698Ala were validated but with very rare frequency (Schulte, Mollenhauer et al. 
2012). Unexpectedly, the original R1205H mutation was found in three controls only 
(Schulte, Mollenhauer et al. 2012). Lesage et al. identified four novel nonsynonymous 
variants out of out of 251 autosomal dominant PD cases, mostly of French origin, including 
p.A433V, p.E465del, p.E462delInsGK, p.P446H, particularly the p.E462delInsGK was 
found in 2 affected siblings with segregation (Lesage, Condroyer et al. 2012). Two 
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previously reported variants were also found in their study, but one was in 2 isolated 
patients and one in a control case (Lesage, Condroyer et al. 2012). Using whole exome 
sequencing of 213 Caucasian PD patients and 272 control individuals, Nuytemans et al. 
confirmed that the initially identified p.R1205H mutation segregated in all affected 
members of a 3-generation family, except for an 86-year-old member (Nuytemans, 
Bademci et al. 2013). In addition, they also identified eight novel nonsynonymous variants 
and two small deletions in isolated PD patients: p.A425V, p.A428M, p.M432V, p.P486S, 
p.V541G, p.A550P, p.P1229A, p.L1233P, pG466_A468del, pE525del. Among those, both 
p.A425V and p.A428M were identified in the same patient (Nuytemans, Bademci et al. 
2013). p.V541G, p.P486S, and pE525del were found in patients only, and p.M432V, 
p.A550P, p.P1229A, p.L1233P were present in both patients and controls (Nuytemans, 
Bademci et al. 2013) (Figure 1). Other screening studies for PD-linked EIF4G1 mutations 
from different ethnic groups including Greek, Italian, African, Chinese, Japanese, and 
Indian, did not identify the initial R1205H and A502V mutants in either patients or control 
groups, nor found any novel variants with strong disease association (Chen, Chen et al. 
2013, Li, Tang et al. 2013, Sudhaman, Behari et al. 2013, Zhao, Ho et al. 2013, 
Blanckenberg, Ntsapi et al. 2014, Gagliardi, Annesi et al. 2014, Nishioka, Funayama et al. 
2014, Kalinderi, Bostantjopoulou et al. 2015). Hence, studies to date indicate that EIF4G1 
mutations are very rare, representing less than 1% of worldwide PD patients (Deng, Wu et 
al. 2015), and their penetrance is incomplete, as the similar situation in LRRK2 G2019S 
mutation (Deng, Le et al. 2005, Trinh, Guella et al. 2014), the most prevalent mutation in 





Figure 1. Mutations or variants identified in the EIF4G1 gene.  
Schematic depicting missense variants in individuals with PD and their relative location in 
relation to known and predicted functional domains. The amino acids number is based on 
NCBI Reference Sequence: NP_937884.1. The red variants are the first reported PD-
associated EIF4G1 mutations. 
PABP: polyadenylate binding protein; eIF: eukaryotic translation initiation factor; MNK: 




Protein translation and neurological disorders 
 
Although the genetic studies of EIF4G1 variants indicated the mutations are rare, 
we believe the study of EIF4G1 mutations will help us know more about PD pathogenesis, 
as eIF4G1 is crucial in protein translation and many studies have revealed that aberrant 
protein translation can lead to various neurological disorders, including neurodegenerative 
disease.  
Translational regulation is an indispensable step for gene expression during 
multiple life activities. Protein synthesis involves a three-stage process of initiation, 
elongation, and termination. Initiation is considered the rate-limiting step. Most mRNAs 
use the canonical 5’ end-dependent scanning translation initiation pathway, while 
translation initiation of 5%-10% of mRNAs are cap-independent, mediated by internal 
ribosome entry sites (IRESs) instead (Jackson, Hellen et al. 2010). A brief overview of the 
protein translation initiation is as following (Figure 2). In eukaryotic cells, mature mRNAs 
are exported from the nucleus to the cytosol after processing including capping with a 7-
methylguanosine residue at the 5’ terminal end, polyadenylation with a poly-adenosine tail 
of about 200 adenylate residues at the 3’end, and splicing off the non-coding RNA introns 
(Izaurralde, Stepinski et al. 1992, Tarun and Sachs 1996). In the cytosol, at the mRNA site, 
forms the cap-binding eukaryotic initiation factor 4F (eIF4F) with eIF4E binding the cap, 
Poly-A Binding Protein (PABP) binding the Poly-A tail, eIF4A attaching and subsequently 
unwinding the 5' untranslated region of mRNA, and eIF4G connecting with each of the 
components (Izaurralde, Stepinski et al. 1992, Tarun and Sachs 1996, Haghighat and 
Sonenberg 1997). Together with the initiation factors such as eIF1, eIF1A, and eIF3, the 
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small ribosomal subunit (the 40S in eukaryotes) and ternary complex, comprising initiator 
methionyl-tRNA ( Met-tRNAi-Met ), eIF2 and GTP, form the 43S preinitiation complex 
(PIC) (Marchione, Leibovitch et al. 2013). The eIF4F cap complex recruits the PIC to the 
mRNA through the interaction of eIF4G and eIF3 and forms the 48S initiation complex 
(Jackson, Hellen et al. 2010). Once the 48S complex is loaded, it scans the mRNA from 5’ 
to 3’ until it reaches a start codon. Upon the recognition of the start codon, the GTP in the 
ternary complex is hydrolyzed with the aid of eIF5. Then eIF5 and eIF5B facilitate the 
dissociation of the initiation factors and the joining of the large ribosomal subunit (the 60S 
in eukaryotes). The large subunit joins to make an 80S ribosome, which has peptidyl 









There are various studies showing a causal link between neurological disorder 
phenotypes with dysfunction of one or more of protein translation machinery components. 
As described above, the level of eIF4E is crucial for cap-dependent translation, and it can 
be sequestered by the eIF4E-binding protein (4E-BP) from binding the eIF4F complex. It 
was reported that eIF4E overexpression or eukaryotic initiation factor 4E-binding protein 
(4E-BP) knockout mice showed the phenotypes similar to autism-spectrum disorders (ASD) 
(Gkogkas, Khoutorsky et al. 2013, Santini, Huynh et al. 2013). Translation of neuroligins, 
postsynaptic proteins that are causally linked to ASDs, was increased as eIF4E dependent. 
eIF2 activation is essential for the assembly of the 43S preinitiation complex and is 
suppressed by phosphorylation of eIF2α. eIF2α-mediated protein synthesis defects have 
shown to be linked with neurodegenerative diseases, such as prion-mediated 
neurodegeneration or Alzheimer’s disease (AD) (Moreno, Radford et al. 2012, Ma, Trinh 
et al. 2013). eIF2 phosphorylation was elevated by the unfolded protein response (UPR) 
triggered by protein aggregation. Then a lot of genes that are critical for neuronal activity 
and synaptic function were downregulated by reduced global translation. Fragile X 
syndrome (FXS) and fragile X-related tremor and ataxia syndrome (FXTAS) are caused 
by loss of function of a single gene, fragile X mental retardation 1 (FMR1), an RNA-
binding protein that has been reported functioning as a translational repressor (Sharma, 
Hoeffer et al. 2010). In the Fmr1 knock-out mouse, the mammalian target of rapamycin 
(mTOR) signaling pathway, which is the master regulator of translation initiation, was 
elevated, resulting over-activation of metabotropic glutamate receptor (mGluR) and 
abnormal synaptic plasticity. Recently, repeat-associated non-ATG (RAN) translation 
initiation has been indicated as a potential underlying mechanism to explain triplet 
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expansion-related homopolymeric protein disorders, such as spinocerebellar ataxia (SCA), 
myotonic dystrophy (DM), and amyotrophic lateral sclerosis (ALS) (Cleary and Ranum 
2013). 
More interestingly, recent studies about the pathogenicity of mutations of LRRK2 
(Leucine-rich repeat kinase 2) have implicated the role of dysregulated protein synthesis 
in PD. The G2019S mutation in the kinase domain of LRRK2 is the most prevalent among 
both familial and sporadic PD cases (Martin, Dawson et al. 2011). Enhanced kinase activity 
of G2019 LRRK2 being responsible for its neurotoxicity has been established by multiple 
genetic and pharmacological studies (Smith, Pei et al. 2006, Lee, Shin et al. 2010). 
Identification of eukaryotic initiation factor 4E-binding protein (4E-BP) as a LRRK2 
kinase substrate initially suggested the possibility of LRRK2 involvement in protein 
translation (Imai, Gehrke et al. 2008). The study, described in a recently published paper 
from our laboratory, provided strong evidence linking pathogenesis of PD to aberrant 
protein synthesis by identification of ribosomal protein s15 (rps15) as a key pathogenic 
kinase substrate of LRRK2 in Drosophila and human neuron PD models (Martin, Kim et 
al. 2014). We showed G2019S LRRK2 increased mRNA translation and protein synthesis 
in bulk via phosphorylation on threonine 136 of rps15, and alanine substitution rescued the 
neurodegeneration caused by increased kinase activity of LRRK2.  
Potential role of eIF4G1 in neurodegeneration 
 
Most of the disease cases in which eIF4G1 plays a role are cancer-related (Deng, 
Wu et al. 2015). eIF4G1 was reported overexpressed in 30% of a particular lung cancer 
and 80% of inflammatory breast cancer (Bauer, Diesinger et al. 2001, Silvera, Arju et al. 
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2009, Tu, Liu et al. 2010). Also, patients with higher eIF4G1 level were found associated 
with shorter survival time in nasopharyngeal carcinoma. PD and cancer are seemingly 
unrelated, but it was raised decades ago that PD patients are protected from certain type of 
cancers, and many epidemiological studies suggest a negative correlation between PD and 
cancer (Strongosky, Farrer et al. 2008). This link between PD and cancer indicates the 
hypothesis that genetic background that can protect an individual from cancer may 
predispose the one for PD (West, Dawson et al. 2005). Several genes later identified as 
PD-associated were studied in cancer research at the beginning. For instance, parkin and 
PINK1 seem to be tumor suppressor genes, while DJ-1 was initially isolated in the screen 
for oncogene (West, Dawson et al. 2005).  
There are several hypotheses regarding the potential involvement of eIF4G1 in PD. 
Some type of PD was reported being induced by viral infection, particularly by influenza. 
And eIF4G1 was showed being targeted by proteases encoded by picornavirus (Foeger, 
Kuehnel et al. 2005, Jang, Boltz et al. 2009). The evidence that eIF4G1 is directly involved 
in virus-induced PD is still warranted. Several seminal studies have suggested the roles of 
microRNAs in PD progressing, including those showed specific microRNA targeting PD-
related genes and PD-related genes regulating microRNA processing machinery (Heman-
Ackah, Hallegger et al. 2013). And eIF4G1 has been suggested facilitating microRNA-
mediated gene down-regulation. So the role of eI4G1 in PD may involve microRNA-
mediated gene silencing.  
As for the role of EIF4G1 mutations in PD, while standard genetic approaches have 
not yet demonstrated that the mutations are causal to PD, biochemical and cellular studies 
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have suggested a potential role of EIF4G1 mutations in neurodegeneration. In co-
immunoprecipitation studies of eIF4G1 mutants from transfected cell lysates, the R1205H 
allele showed reduced interaction between eIF4G1 and eIF3E, which may hamper 
eIF4G1’s function as a molecular bridge for 43S complex loading (Chartier-Harlin, 
Dachsel et al. 2011, Villa, Do et al. 2013). Furthermore, A502V eIF4G1 has been shown 
to perturb its binding to eIF4E, suggesting that cap-dependent translation may be affected 
(Sonenberg and Hinnebusch 2009, Chartier-Harlin, Dachsel et al. 2011). In addition, the 
mitochondrial membrane potential of mutant eIF4G1 overexpressed cells were 
substantially reduced with hydrogen peroxide treatment compared to wildtype eIF4G1 
overexpressed cells, suggesting that eIF4G1 mutants may have defective stress response 
pathways (Chartier-Harlin, Dachsel et al. 2011). There is also evidence showing that 
eIF4G1 interacts with -Syn (Dhungel, Eleuteri et al. 2015). In a yeast -Syn model, 
overexpression of yeast eIF4G1 homolog TIF4631 or human eIF4G1 suppressed -Syn 
toxicity, while upregulation of R1205H eIF4G1 was not able to suppress the toxicity.  
Also, cellular level of wildtype eIF4G1 was reported to be crucial in its 
neuroprotective role in the ischemia-induced neuronal death. Vosler et al. showed that 
calpain, a protease activated by ischemia, degrades eIF4G1 and leads to persistent protein 
synthesis inhibition (Vosler, Gao et al. 2011). The authors showed that the protein 
synthesis rate was correlated with the viability of oxygen-glucose deprivation (OGD) 
treated primary neurons, and eIF4G1 overexpression increased neuronal viability after 
OGD treatment. These studies suggest that mutations of eIF4G1 may alter its function 
under stress conditions, resulting in neurodegeneration.  
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Further studies on EIF4G1 mutations including genetic association to PD as well 
as a molecular pathologic mechanism are warranted, including examining the effects of 
EIF4G1 mutations on translation and neuronal viability in animal models.  In my thesis, I 
demonstrated that mutations of EIF4G1 might be disease-causing in a transgenic 
Drosophila model, and proved the eIF4G1 mutants affect protein synthesis in knock-in 
cells. The next chapter is about how I generated EIF4G1 WT, RH, and AV transgenic flies 
and characterized their motor behavior, lifespan, and dopaminergic neuron numbers. The 
mutation-bearing transgenic flies showed PD-like phenotypes including locomotion defect, 





Development of Transgenic Drosophila expressing the WT/RH/AV EIF4G1 for 
Parkinson’s disease modeling 
Introduction 
Parkinson’s disease (PD) is the most common movement disorder with a prevalence 
of approximately 1% of the population at the age of 65 and rising to 5% of the population 
at the age of 85 (Lang and Lozano 1998, Lang and Lozano 1998). The cardinal symptoms 
including resting tremor, bradykinesia, rigidity and postural instability are attributable to 
the selective loss of dopaminergic neurons in substantia nigra pars compacta (Fahn 2003). 
PD had been considered as a typical sporadic disorder until recent two decades, 
identification of an increasing number of single genetic loci responsible for inherited PD 
with Mendelian pattern has drawn more and more attention into familial PD cases (Moore, 
West et al. 2005, Martin, Dawson et al. 2011). Monogenic PD and sporadic PD share many 
features including the pathological hallmark of PD, loss of nigrostriatal DAergic neurons. 
Discovery of PD-associated gene defects brings new insight into the potential pathogenic 
pathways of PD and other neurodegenerative diseases.  
In 2011, the mutations of EIF4G1 gene were identified as a potential cause of 
autosomal dominant familial Parkinson’s disease in a genome-wide linkage analysis 
(Chartier-Harlin, Dachsel et al. 2011). EIF4G1 encodes a protein named eIF4G1 
(eukaryotic translation initiation factor 4, gamma 1), one of the three paralogs of eIF4G 
(Yan and Rhoads 1995, Coldwell, Sack et al. 2012). eIF4G is a scaffold component in 
mRNA translation initiation complex, performing a key role in both cap-dependent and 
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cap-independent translation initiation (Sonenberg, Morgan et al. 1978, Jackson, Hellen et 
al. 2010). In cap-dependent translation, together with PABP and eIF4E, eIF4G circularizes 
the mRNA to stabilize it, and to promote initiation (Gallie 1991). Working with eIF3, 
eIF4G assists the 43S pre-initiation complex loading to the mRNA (Andreou and 
Klostermeier 2013, Marchione, Leibovitch et al. 2013). In cap-independent translation 
initiation, eIF4G binds with eIF4A to form a sub-complex, thereby initiates translation by 
recruiting 43S complex onto internal ribosome entry site (IRES) without the cap-binding 
eIF4F complex (Pelletier and Sonenberg 1988, Ali, McKendrick et al. 2001, Svitkin, Herdy 
et al. 2005). However, following sequencing studies indicated mutations of EIF4G1 
seemed to be rare, standard genetic approaches have not been able to confirm the mutations 
are causal (Deng, Wu et al. 2015). The question we wanted to ask was if the mutations 
could cause PD-like phenotypes in genetically engineered animal models.  
Currently, there are no ideal murine models for PD, so the development of 
Drosophila model fills some of the gaps as a powerful tool to study PD.  Flies propagate 
fast, and their life spans are within 2-3 months, this is a huge time advantage for the study 
of age-related disease compared with around 24 months of lifespans of mice (Vanhauwaert 
and Verstreken 2015). Flies are capable of performing complex motor behaviors like 
climbing and flying, and their brains are complex enough to make these behaviors relevant 
to humans (Ali, Escala et al. 2011). Their DAergic neurons are clustered and amenable to 
staining and imaging, by manually counting the DAergic neurons one can easily evaluate 
if there is DAergic neuron loss which is the hallmark of Parkinson disease phenotype 
(Marsh and Thompson 2006). And the availability of very potent genetic tools including 
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mutagenesis by transposons, loss-of-function screen by RNAi, and GAL4 and UAS system 
(Venken and Bellen 2007).  
One of the most widely and powerful uses of the GAL4/UAS system is to generate 
a transgenic animal model for tissue-specific expression of a chosen gene (Elliott and 
Brand 2008). The yeast GAL4 transcription activator can be induced by the temporal and 
spatial endogenous enhancer/promoter elements. The transgene is cloned into a construct 
with minimal promoter linked with upstream activator sequences (UAS) which can be 
specifically recognized by GAL4. GAL4 binds the UAS and induces UAS-linked gene 
expression. When a UAS-linked transgenic line is crossed with tissue-specific promoter-
linked GAL4 driver line, the F1 progeny bearing the two transgenes will express the UAS-
linked gene in a tissue-specific manner. The Drosophila research community has 
accumulated many different types of GAL4 lines under different tissue specific promoter 
or other inducible promoters including heat shock, steroid, etc. Individual researchers just 
need to generate UAS lines by cloning their gene of interest into UAS construct then 
crossing the UAS lines with different GAL4 lines depending on their research purposes. As 
for the UAS lines, the insertion location of UAS-linked gene into the fly genome can affect 
the expression of the transgene. There have been a variety of UAS constructs utilizing 
different systems to control the insertion locations.  
In my thesis project, I have tried three different techniques generating the UAS lines, 
and I have selected the optimal strategy for making the UAS-linked human wild type (WT) 
EIF4G1, R1205H EIF4G1, and A502V EIF4G1 lines and crossed with tyrosine 
hydroxylase (TH)-GAL4 lines to induce transgene expression in dopaminergic neurons. 
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During characterization, our tissue-specific transgenic flies showed age-dependent 
locomotion defect, reduced lifespan, and neuronal degeneration.  
Results 
Generation of a tissue-specific Drosophila model of PD: EIF4G1 transgenic flies 
We have generated tissue-specific WT-EIF4G1, R1205H-EIF4G1, and A502V-
EIF4G1 transgenic flies using the GAL4/UAS system. Since the TH-GAL4 line, in which 
GAL4 is regulated under the promoter of Drosophila tyrosine hydroxylase (DTH) gene 
(Friggi-Grelin, Coulom et al. 2003), is already available in the Bloomington Drosophila 
Stock Center, I focused on generating the UAS-WT-EIF4G1, UAS-R1205H-EIF4G1, and 
UAS-A502V-EIF4G1 lines. UAS lines are made through germline transformation by 
embryo injection of the construct with the gene of interest and transformation elements. 
The traditional and widely used transformation method relies on P-element transposon 
system (Castro and Carareto 2004). P-element, originally found in the fly genome, contain 
two terminal repeats and are capable of transposition with the DNA flanked by the terminal 
repeats when catalyzed by P transposase (Rubin and Spradling 1982). The P-element 
transformation vector has been developed with P-element ends and a range of visible or 
selectable marker genes, the most widely used is the mini-white gene (Karess and Rubin 
1984, Klemenz, Weber et al. 1987). Individual experimenter just needs to clone the DNA 
of interest into the P-element transformation vector and co-inject with the helper plasmid 




As the R1205H mutation was the first variant identified, we started with making 
the WT-EIF4G1 and R1205H-EIF4G1 UAS line. We cloned the WT EIF4G1 and RH 
EIF4G1 into the pUAST vector (Figure 3) and obtained seven transformants. We crossed 
the UAS lines with the pan-neuronal GAL4 driver line, Embryonic Lethal Abnormal Visual 
(Elav)-GAL4 to obtain the progenies with transgene expression in the whole brain 
(Koushika, Lisbin et al. 1996). Then we checked the transgene expression by collecting 
the fly head and running the brain lysate on SDS-PAGE. Western blot by anti-human-
eIF4G1 showed the expression levels cross the lines. As P-element induced transgene 
insertion is random, ideally, we need to have at least two lines of WT EIF4G1 with 
transgene expression level similar to at least two lines of RH EIF4G1, but we could not 
find the desired lines to proceed (Figure 4). We also detected the mRNA level of the 
transgene by real-time PCR and found the amounts of mRNA of transgene across the lines 
were consistent with the protein levels (Figure 5). It indicated that the protein expression 
differences were caused by the transcription level, since all mRNAs of the transgene had 
same sequence except for the point mutation, the variation of mRNA levels may be 
attributed to the endogenous genomic elements as the transgene were inserted in different 








Figure 3. Schematic representation of the pUAST-EIF4G1 construct for embryo 
injection. 
The human EIF4G1 CDS was subcloned in between the Kpn1 and Xba1 multi-cloning 
sites of the backbone pUAST vector (Brand and Perrimon 1993), which contains five 
tandemly arrayed optimized GAL4 binding sites (UAS), hsp70 promoter, and SV40 small 
T intron. These features are included in a P-element vector (pCaSpeR3) containing the P-
element ends and the selective marker white gene. 
 
Figure 4. Representative Immunoblots of eIF4G1 expression in transgenic flies 
generated by P-element-mediated transformation. 
Three lines of UAS-WT-EIF4G1, three lines of UAS-RH-EIF4G1, and non-transgenic 
w1118 line were crossed with ELAV (embryonic lethal abnormal visual system)-GAL4 line, 
with pan-neuronal expressed GAL4. Thirty F1 progenies bearing both GAL4 and UAS were 
selected for the marker gene, fly heads were harvested and homogenized, protein lysates 
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were analyzed by SDS-PAGE, and human eIF4G1 expression levels were detected by 




Figure 5. Quantitative PCR of eIF4G1 mRNAs in transgenic flies 
For the TH-GAL4; UAS-EIF4G1 and the control line flies, mRNAs were extracted and 
reverse-transcribed. cDNA was amplified by EIF4G1 primers and tubulin (housekeeping 
gene control) primers and quantified. The relative mRNA levels of EIF4G1 of all the lines 







It has been long realized that the “position effects” of random insertion of P-
element into the chromatin cause the various expression level of the transgene (Bellen, 
Levis et al. 2004). Researchers have developed the site-specific integration system induced 
by the PhiC31 integrase (Groth, Fish et al. 2004). Isolated from the bacteriophage PhiC31, 
the PhiC31 integrase could mediate the unidirectional sequence-specific recombination 
between two largely different DNA fragments, called attB and attP (Figure 6). The 
efficiency of the system has been optimized by several groups. Konrad Basler’s group 
developed a list of lines that have attP landing sites inserted into the Drosophila major 
chromosomes, and also the Phic31 integrase engineered into fly genome eliminate the need 
to inject the integrase gene (Bischof, Maeda et al. 2007). One can easily clone the gene of 
interest into the plasmid with an attB site and inject the construct into the flies embryo with 
attP site and PhiC31 gene incorporated in the genome. While the PhiC31 system reduces 
the position effect of random insertion of the transgene, the options of a broad range of 
expression levels of the transgene are also limited. Rubin’s group found that by increasing 
the copy number of UAS from 5 to 10, the transgene expression level can be doubled 
(Pfeiffer, Ngo et al. 2010). Then they developed a set of plasmids with UAS sites from 5 
to 40 and found that the transgene expression level correlated with the number of the UAS 
sites. So I chose to clone the WT-EIF4G1, R1205H-EIF4G1, and A502V-EIF4G1 into the 
Basler’s group’s pUASTattB-5XUAS as well as the optimized pJFRC-10XUAS, pJFRC-
20XUAS vectors (Figure 7). 
We tested the constructs in a Drosophila S2 cell line by co-transfection of the UAS-
EIF4G1 vector with or without GAL4 vector. Clearly, human eIF4G1 were more robustly 
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expressed in the pJFRC-EIF4G1 transfected cells than the pUASTattB-EIF4G1 transfected 
cells with GAL4 induction. (Figure 8). There was no obvious difference of expression of 
eIF4G1 between pJFRC-10xUAS-EIF4G1 and pJFRC-20xUAS-EIF4G1 transfected cells. 
It could be explained that the protein expression machinery is saturated in both conditions 
due to the excessive transfection of the plasmids.  
We then tested the transgene expression in the transgenic flies by crossing the UAS 
lines with ElAV-GAL4 line and collecting the fly heads for Western Blot. In contrast to 
transgenic flies overexpressing eIF4G1, ELAV-GAL4 line and non-transgenic flies were 
used as a negative control that do not express the exogenous EIF4G1 transgene in the 
subsequent experiments and the groups are noted as "controls". The signal of eIF4G1 
protein in flies made by pUASTattB-5xUAS was barely seen compared with the flies made 
by the pJFRC vector (Figure 9A).  The transgene expressions of the flies made by pJFRC-
20xUAS were more robust than the flies made by pJFRC-10xUAS and equal across the 
lines (Figure 9A). As eIF4G is considered highly expressed across the tissues, we chose to 
use the high expression transgenic flies made by pJFRC-20xUAS. Since the WT-EIF4G1, 
RH-EIF4G1, AV-EIF4G1 DNAs are inserted in the same location of the fly genome, we 





Figure 6. Schematic showing phiC31-mediated integration of pUASTattB vector into 
the attP landing sites 
The EIF4G1 CDS was sub-cloned into the pUASTattB vector, which contains a 285-bp 
attB fragment, a single loxP site in addition to the other features in the pUAST construct. 
The phiC31 integrase mediates integration of attB-linked plasmid into the attP site, 
creating the two hybrid attL and attR sites, which are not targetable by the phiC31 integrase. 
The loxP sites allow removing of the unnecessary sequences before or after integration of 
pUASTattB. 
 
Figure 7. Diagram of pJFRC-EIF4G1 constructs with different copy numbers of UAS 
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EIF4G1 CDS fragment was sub-cloned into the pJFRC plasmids by the “cut-blunt-cut” 
method described in the Materials and Methods. pJFRC vectors contain different copy 




Figure 8. GAL4-induced expression of eIF4G1 in S2 cells 
Drosophila S2 cells were transfected with UAS-EIF4G1 constructs together with or 
without GAL4 plasmid. Cells were harvested and subjected to Western blot analysis using 




Figure 9. eIF4G1 expression in transgenic flies 
(A). eIF4G1 expression in transgenic flies made by pUASTattB, pJFRC-10xUAS, and 
pJFRC-20xUAS. Indicated UAS-EIF4G1 transgenic lines, wild-type w1118 line, and 
eIF4G knock-down 17002 line were mated with the ELAV-GAL4 line. Fly heads extracts 
were fractionated and subjected to immunoblot analysis using anti-eIF4G1 antibody (20 
g of protein per lane). (B). Transgene expressions were confirmed in selected lines. WT3, 






Early mortality in EIF4G1 RH, AV transgenic flies 
To express eIF4G1 in DAergic neurons, we crossed UAS-WT-EIF4G1, UAS-RH-
EIF4G1, and UAS-AV-EIF4G1 with a tyrosine hydroxylase (TH)-GAL4 line. The non-
transgenic w1118 line was also crossed with TH-GAL4 flies as a control. About 125 
progenies bearing TH-GAL4 and UAS-EIF4G1 or Control were collected based on the 
selective markers. Mortality record of all the lines were taken, and survival curve was 
plotted. Expression of WT-EIF4G1 was benign for the flies as there was no significant 
difference between TH-GAL4; UAS-WT-EIF4G1 flies and control flies. However, 
expression of either RH-EIF4G1 or AV-EIF4G1 caused premature mortality compared 
with WT-EIF4G1 expressing flies. Interestingly, TH-GAL4; UAS-AV-EIF4G1 flies showed 
more severe mortality than TH-GAL4; UAS-RH-EIF4G1 flies (Figure 10). The mean 
lifespans of RH-EIF4G1 and AV-EIF4G1 transgenic flies survived were 54 and 40 days, 
respectively, while the mean lifespan of TH-GAL4; UAS-WT-EIF4G1 was 62 days. The 
ages at which 50% of the RH-EIF4G1 and AV-EIF4G1 transgenic flies survived were 54 
and 39 days, respectively. Compared with 65 days of 50% survival of TH-GAL4; UAS-
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Figure 10. Expression of mutant eIF4G1 induced by TH-GAL4 caused early mortality 
(A) Survival curves of non-transgenic w1118, transgenic UAS-WT-EIF4G1, UAS-RH-
EIF4G1, and UAS-AV-EIF4G1. Mortality of cohorts of 125 flies each genotype were 
recorded every three days. (B) Statistical analysis results comparing each line with the 
others.  





























Late-Onset locomotion impairment in EIF4G1 RH, AV flies 
 
PD is typically diagnosed and characterized by motor symptoms caused by the 
neurodegeneration (Lang and Lozano 1998, Lang and Lozano 1998). In flies, locomotion 
defective phenotypes can be tested by climbing assays, as flies are negatively geotactic, i.e. 
flies move opposite the gravitational vector as an innate escape response (Gargano, Martin 
et al. 2005). So we performed negative geotaxis assay to test if there was behavior defect 
caused by expression of eIF4G1 mutations in DAergic neurons. We set up the same cross 
described in the survival experiment. We collected a vial of 25 flies and five vials for each 
line. Flies were displaced to the bottom of the vial and their climbing height within 3 
seconds was recorded individually. We found that the climbing ability of all the lines 
declined as they were aging. And at early age, the flies expressing mutant eIF4G1 climbed 
as well as WT EIF4G1 and the control flies. However, as their age increased to 5 weeks, 
the performance of the mutant flies declined more rapidly than WT transgenic and Control 
flies. Moreover, AV-EIF4G1 flies showed more severe motor defects than RH-EIF4G1 









Figure 11.  Expression of eIF4G1 mutant protein by TH-GAL4 driver caused 
locomotion impairment. 
Cohorts of 125 flies each genotype were subjected to negative geotaxis assay weekly 
(ANOVA, Bonferroni posttest, ***p<0.001, **p<0.01, n=5 groups of 25 flies per group). 
(A) Average climbing height within 3 seconds was plotted. (B)  Representative pictures of 












































Age-related dopaminergic neurodegeneration in EIF4G1 RH, AV Transgenic flies 
The pathological hallmark of PD is the neurodegeneration of DAergic neurons in 
the SNc. To assess whether eIF4G1 mutations leads to DAergic neuron degeneration, I 
collected and dissected the brains of the same batch of flies as described in the negative 
geotaxis test at the age of 1 week and 6 week. The brains were immunostained for DAergic 
neuron-specific marker tyrosine hydroxylase (TH), an enzyme that catalyzes the synthesis 
of dopamine. I focused on the five major clusters of DAergic neurons in the central brain 
that can be noted according to their anatomical position and targeted by TH-GAL4. They 
are: paired posterior lateral 1 and 2 (PPL1 and PPL2); paired posterior medial 1 and 2 
(PPM1/2) which are often grouped together because of their proximity; paired posterior 
medial 3 (PPM3); paired anterior lateral (PAL). TH-positive neurons within each cluster 
were manually counted through confocal Z-stacks. For one week old flies, there was no 
difference of DAergic neuron numbers among all the lines (Figure 12). However, at six 
weeks of age, the TH-positive neurons in PPL1, PPM1/2 clusters were significantly less in 
RH-EIF4G1 and AV-EIF4G1 flies than WT-EIF4G1 and Control flies. And there was 
DAergic neurons loss in PPM3 of AV-EIF4G1 flies compared with WT-EIF4G1 and 





Figure 12. Expression of eIF4G1 mutant by TH-GAL4 driver did not cause DAergic 
neuron death at early age. 
Dissected whole brains were subjected to anti-TH immunofluorescent staining. (A) 





Representative images of the anti-TH staining in whole brain of each genotype at 1-week 
age.   
  






Dissected whole brains were subjected to anti-TH immunofluorescent staining. (A) 
Average TH-positive neurons in each cluster of each genotype at 5-week age. (B) 
Representative images of the anti-TH staining in the whole brain of each genotype at 5-
week age. (ANOVA, Bonferroni posttest, ***p<0.001, **p<0.01, *p<0.05, n=10 fly brains 
per genotype) 
Discussion 
We have generated a Drosophila model of PD that expresses human eIF4G1 in 
dopaminergic neurons by crossing UAS-EIF4G1 lines with the available TH-GAL4 line. 
For the TH-GAL4 line, yeast transcriptional activator GAL4 gene use the 
enhancer/promoter of the Drosophila Tyrosine Hydroxylase (DTH) gene that specifically 
expressed in all dopaminergic cells (Friggi-Grelin, Coulom et al. 2003). DTH encodes the 
enzyme catalyzing the rate-limiting step in dopamine biosynthesis. To generate the 
construct for germline transformation for UAS line, we tried three different plasmids. The 
traditional pUAST plasmid utilizing P-element system did not give us at least two lines 
from each genotype showing similar transgene expression level (Figure 4). The 
pUASTattB-5xUAS plasmid was developed based on the site-specific PhiC31 integrase 
system. It overcomes the drawback of position effect of P-element, but limits the range of 
transgene expression level. We eventually moved to the set of plasmids developed by the 
Rubin lab at Janelia Research Campus, which contain different copy numbers of UAS 
sequence (Pfeiffer, Ngo et al. 2010). The flies generated by pJFRC-20xUAS showed the 
robust transgene expression, and the levels across the lines were equal (Figure 9).  
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Expression of RH-EIF4G1 and AV-EIF4G1 in dopaminergic neurons led to reduced 
life span compared with WT-EIF4G1 and Control flies (Figure 10). Moreover AV-EIF4G1 
flies showed shorter lifespan than RH-EIF4G1 flies. Early mortality has been observed in 
other Drosophila models expressing PD genes associated to both early-onset and late-onset 
parkinsonism (Lavara-Culebras and Paricio 2007, Liu, Wang et al. 2008). EIF4G1 R1205H 
was identified in a late-onset family, and the majority of patients’ data suggested EIF4G1 
R1205H associated with late-onset PD (Chartier-Harlin, Dachsel et al. 2011). These may 
partially reflect the smaller difference in lifespan between RH-EIF4G1 and WT-EIF4G1 
flies. As there were few studies regarding the association of AV mutation to the age of PD 
onset, it is hard to draw the link between AV mutation and early onset PD just based on 
our fly data.  
Both RH-EIF4G1 and AV-EIF4G1 flies had locomotion defects compared with 
WT-EIF4G1 and Control flies in a negative geotaxis test (Figure 11). As the assay utilizes 
the natural tendency of flies to move against gravity when disturbed, it has been well 
accepted as the standard method to measure fly motor function. Interestingly, the motor 
impairment of both mutation flies manifested at a relatively late age. It indicated that the 
locomotion defect caused by the mutations was age-dependent. Besides negative geotaxis, 
we can also perform Actometer Test, which measures the mobility of flies in quiet status, 
to have a comprehensive profile of the locomotor activity of the flies.  
We found less TH-positive neurons in both RH-EIF4G1 and AV-EIF4G1 flies than 
those in WT-EIF4G1 and Control flies, and the loss was age-related (Figure 12). As PD is 
characterized by progressive degeneration of DAergic neurons among other 
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neurodegenerative diseases, our results indicated the EIF4G1 mutations caused the most 
typical PD-like phenotype. Significant loss of dopaminergic neurons were shown in 3 
clusters out of 5, and the largest percentage of neuronal loss, about 20%, was seen in PPL1 
cluster.  The Drosophila models expressing other PD-associated mutations showed 
DAergic neuron loss either in all or specific clusters, and percentage loss varied. It could 
due to either different clusters have a different tolerance for the toxicity caused by the 
mutations, or different clusters have different TH expression levels which cause different 
transgene expression level. It is known that cluster-specific neurons innervate distinct 
functional areas of the brain, but the particular functional effect controlled by the specific 
cluster is not completely characterized (Riemensperger, Isabel et al. 2011). We have not 
tested if the mutations could cause dopaminergic neuron specific loss when overexpressed 
in TH neurons and other brain regions. We can cross our UAS lines with either dopa 
decarboxylase (ddc)-GAL4 driver line (Feany and Bender 2000), in which GAL4 is 
expressed in both TH and serotonin (5-HT) neurons or ElAV-GAL4 line. One caveat should 
be pointed out that the GAL4 expression varies in different driver lines. We may not 
observe the same phenotype due to the change of expression level of the transgene. But it 
can be overcome by using UAS lines with more copy numbers of UAS sequence  
In conclusion, we have tested a Drosophila model of PD-associated EIF4G1 
mutations. We provided the in vivo evidence of a potential causal link between EIF4G1 
mutations and PD-like phenotypes. The RH-EIF4G1 and AV-EIF4G1 Transgenic flies had 
early mortality, late-onset locomotion impairment, and age-related dopaminergic 
neurodegeneration, while the WT-EIF4G1 flies performed the same as the non-transgenic 
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flies. While the fly model has limitations, its short lifespan and low-cost maintenance 
features enable us to test different hypothesis of the underlying mechanisms of 




Materials and Methods 
Generation of the constructs for UAS-EIF4G1 Transgenic lines 
Construct generation by cloning 
pUAST-WT-EIF4G1: Full-length human EIF4G1 (NM_198241.2) was cloned into 
the pUAST vector (Brand and Perrimon 1993) between Kpn1 (NEB) and Xba1 (NEB) 
restriction sites. pUAST-RH-EIF4G1 and pUAST-AV-EIF4G1 were generated by site-
directed mutagenesis of the pUAST-WT-EIF4G1 using the QuikChange II XL Site-
Directed Mutagenesis Kit (Agilent Technologies) and verified by sequencing.  
pUASTattB-EIF4G1: Full-length human wild type or mutant EIF4G1 were 
subcloned from pUAST constructs into the pUASTattB plasmids (Bischof, Maeda et al. 
2007) between Kpn1(NEB) and Xba1 (NEB) restriction sites.  
pJFRC-EIF4G1: After looking for the restriction sites on the parent vector and 
destination vector, we found there was only one matching site, so we used the “cut-blunt-
cut” cloning method. First, the parent vector pUASTattB-EIF4G1and pJFRC12-10xUAS 
were cut by Sac1 (NEB) and Xho1 (NEB) respectively. Then the overhangs were made 
blunt by the Quick Blunting Kit (NEB). Both plasmids were purified by gel electrophoresis 
and proceeded with second cutting by Xba1. After the second purification, both the 
EIF4G1 insert and the pJFRC12-10xUAS and had a blunt end and sticky end. Then 
standard ligation reaction was applied to generate the intact construct using the Quick 





Construct function test in Drosophila S2 cells 
 
All the constructs were verified by sequencing and amplified by maxiprep (Qiagen) 
(primers in Table 4 ). Then Drosophila S2 cells (Gibco) were transfected with either the 
pJFRC-10xUAS-EIF4G1 construct alone or together with pCasperAUG-GAL4-X  
(Vosshall, Wong et al. 2000) S2 cells were cultured in Schneider's Medium (Gibco) plus 
10% FBS (Gibco) and 1% Penstrep (Gibco) and plated at 5*10^5 cells/well in 6-well plate 
(Corning). Around 1*10^6 cells in one well of six-well plate were transfected with 1ug of 
DNA by X-tremeGENE™ HP DNA Transfection Reagent (Roche). 24 hours after 
transfection cells were collected for protein level test by Immunoblot.  
Immunoblot Analysis 
Cells were harvested in chilled PBS and centrifuged to remove PBS. Then cells 
were resuspended in the cell lysis buffer and lysed on ice for 30 minutes. The cell lysate 
was centrifuged at 14,000 g for 30 min, and the supernatant was collected. Total protein 
amount was quantified by the BCA protein assay kit (Pierce) with BSA standards and 
analyzed by immunoblotting. Then the concentration of each sample was adjusted to equal 
by adding the cell lysis buffer. 4X Laemmli Sample buffer (Bio-Rad) containing 5% 2-
Mercaptoethanol (Sigma) was added to the supernatant for sample preparation. Then the 
samples were boiled for 10 minutes and cooled to room temperature. The lysate samples 
were run in the Running Buffer through 8% SDS-PAGE gels made by 30% acrylamide/bis 
solution, 29:1 (3.3% C) (Bio-Rad) and transferred in the Transfer Buffer to nitrocellulose 
membranes. Protein bands were checked by Ponceau S dye (Sigma-Aldrich). Membranes 
were blocked with 5% non-fat milk in TBS-T buffer and then incubated with primary 
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antibodies diluted in blocking solution (2.5 % nonfat milk overnight at 4°C or 2 hours at 
room temperature) followed by 1 hour incubation with HRP-conjugated secondary 
antibodies (1:2,500). The immunoblot signal was detected using chemiluminescent 
substrates (Supersignal West Pico/ Femto chemiluminescent substrate, Thermo Scientific) 
Characterization of the EIF4G1 Transgenic Drosophila model 
UAS-EIF4G1 founder line generation, stock keeping, and mating set up 
The selected constructs were microinjected in fly embryos (BestGene, Inc.), and 
we chose the 24749 strain (Basler strains (PhiC31 strains) as the attP host line, with attP 
inserted in 3R-86F on the genome. We received the positive marker identified and balanced 
adult flies. Transgene insertion and EIF4G1 mutation were confirmed by Sanger 
sequencing. All the flies were maintained on standard corneal medium in 8 dram vial 
(Genesee Scientific) at 25 Celsius/60% relative humidity under a 12 hour light-dark cycle. 
Flies selected for mating were firstly transferred from vials to 6oz Square Stock Bottles 
(Genesee Scientific) with food and a small amount of live baker’s yeast for expanding. The 
new generation of flies merged after 10 days. Virgin female flies were collected within 8 
hours after clearing the adults at the beginning of the day. To set up the cross, around 10 
virgin female flies of UAS-EIF4G1 lines were put together with the same number of male 
ELAV-GAL4 flies in the bottle. We used the estimation that 50 male flies for the experiment 
can be collected in one bottle of crossing. Then we set up the crossing bottles based on the 




Transgene expression test 
UAS-EIF4G1 lines were crossed with ELAV-GAL4 line to generate the flies with 
the transgene expression in the whole brains. 30 ELAV-GAL4; UAS-EIF4G1 flies were 
collected into the 1.5ml tube and froze on the dry ice. Fly heads were separated by 
vortexing for 30 seconds and picked manually into a new tube on the ice. Extraction buffer 
(1% NP-40, 50 mM Tris-HCl, 150 mM NaCl, 5 mM EGTA, protease inhibitor cocktail) 
was added to the tube and fly heads were homogenized by a motor-driven pestle (Kimble®). 
Then the tissue was lysed on ice for 30 minutes and centrifuged at 14,000 g for 30 min. 
The supernatant was collected and proceeded as the method described in the Immunoblot 
Analysis section. The 20xUAS EIF4G1 lines were chosen for the characterization 
experiments.  
Real-time PCR of transgene 
 
Fly heads were collected and homogenized, mRNAs were extracted by using the 
RNeasy Plus Mini Kit (Qiagen). cDNA was reversed transcribed using SuperScript® III 
First-Strand Synthesis Kit for RT-PCR (Thermo Scientific) using oligo(dT) primer. 
Transcription levels were measured by real-time PCR using SYBR green master mix 
(Applied Biosystems) and primers for tubulin and EIF4G1.  
Survival curve 
 
UAS-WT-EIF4G1, UAS-RH-EIF4G1, and UAS-AV-EIF4G1 flies were mated with 
TH-GAL4 flies, and the progenies of TH-GAL4; UAS-EIF4G1 had transgene expressed in 
their dopaminergic neurons. 5 vials of 25 flies/vial were monitored for survival. Flies were 
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maintained on regular food and transferred to new vials of food every three days. Mortality 
was scored at the same time. Kaplan-Meier survival curve was plotted and analyzed by 
JMP (SAS Institute, Inc., Cary, NC).  
Negative geotaxis test 
Cohorts of 100 flies from each genotype were maintained at 20 flies/vial and 
transferred to fresh food every 3 or 4 days. For each experiment, flies were transferred to 
the empty 8-gram vials and allowed to rest for 30 seconds. Then the vials were tapped three 
times so that all the flies were displaced to the bottoms of the vials to initiate climbing. 
After 3 seconds, the positions of the flies were captured by the fixed digital camera. The 
climbing assays were performed once a week using the same protocol at the same time of 
the day. The data analysis was done by following the method described in (Rapid iterative 
negative geotaxis (RING): a new method for assessing the age-related locomotor decline 
in Drosophila). The digital images were processed to 8cm high and gray sale using 
Photoshop (Adobe). Then the images were analyzed by using the Analyze Particle 
command in Scion Image (PC version of NIH Image, Scion Corporation, Frederick, MD) 
for the positions for each fly in the vial as X-Y coordinates. The Y values, as the indication 
of the climbing height within the time period, were grouped for each line at each time point. 
The statistics analysis was performed in Prism (GraphPad Software, San Diego, CA)  
Dopamine Neuron Immunohistochemistry 
Cohorts of 20 flies of each genotype were used for brain dissection for 
immunostaining at 1-week age and 7-week age respectively. Following the methods 
previously described in (Wu and Luo, 2006), fly brains were dissected into chilled 4% 
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paraformaldehyde, followed by fixation and permeabilization in room temperature. After 
3 times of 20-minute wash in 0.3% (vol/vol) PBT (1.5 ml Triton-X 100 to 498.5 ml PB) in 
room temperature, 5% (vol/vol) normal goat serum (Lampire Biological 
Laboratories)/PBT was used in blocking. The brains were stained with primary antibody 
against tyrosine hydroxylase for two nights and secondary Alexa Fluor 488 goat anti-
mouse IgG for another two nights. After wash, mountant reagent (ProLong® Gold 
Antifade Mountant, ThermoFisher) was added, and brains were mounted on the slides. 
Each brain was imaged by confocal microscopy. Z-stacks were taken at 1um slice intervals. 
TH-positive neurons were counted and recorded in each cluster of PPM1/2 (protocerebral 
posterior medial 1/2), PPM3, PPL1 (protocerebral posterior lateral 1), and PPL2 clusters 
per hemisphere.   
Materials 
 
Buffer stock solution 
 
All stock solutions were prepared with picopure purified deionized and distilled 
water (ddH2O) and filtered or autoclaved as necessary. 10X Phosphate buffered saline 
(PBS) was prepared by mixing 80 g of NaCl, 14.4 g of Na2HPO4, 2 g of KCl, and 2.4 g of 
KH2PO4 and making the final volume to 1L. The pH was adjusted to 7.4, and the solution 
was filtered and diluted to 1X before use. 10X electrophoresis running buffer was prepared 
by mixing 30.2 g of Tris base, 144.14g of Glycine, and 10 g of sodium dodecyl sulfate 
(SDS) per 1 L preparation. 10X transfer buffer was prepared by mixing 30.2 g of Tris base, 
and 144.14 g of Glycine per 1L preparation. 10X Tris Buffered Saline (TBS) buffer was 
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prepared by mixing 24.23 g of Tris, and 87.75 g of NaCl per 1 L preparation. For a 1X 
working solution of TBS-tween, 1 mL of the detergent Tween-20 was added to 1 L of 
diluted 1X TBS buffer. Cell lysis buffer was freshly made on the same day of each 
experiment, and the recipe is 50mM Tris pH 7.8, 150mM NaCl, 1%NP-40, 0.1% SDS, 
5mM EGTA, and protease inhibitor cocktail. Protease inhibitor cocktails were produced 
by mixing various protease inhibitors as described in the table below, stored in -20 °C in 
aliquots, and freshly added to lysis buffer for total protein lysates preparation. 
 
Chemical Company Concentration (1X) Solvent 
AEBSF Sigma-Aldrich 0.5 mM water 
Aprotinin Roche 4 ug/mL water 
Bestatin Sigma-Aldrich 5 ug/mL water 
E-64 Roche 10 ug/mL water 
Leupeptin Roche 10 ug/mL water 
Pepstatin Sigma-Aldrich 1 ug/mL ethanol 
 






Conjugant Antigen Species Supplier Titer Application 






HRP -Actin mouse Sigma-Aldrich 1:10,000 WB 
HRP V5 mouse Invitrogen 1:5000 WB 
HRP FLAG mouse Sigma-Aldrich 1:5,000 WB 
HRP c-Myc mouse Invitrogen 1:5000 WB 
HRP mouse IgG sheep GE Healthcare 1:2,500 WB 
HRP rabbit IgG donkey GE Healthcare 1:2,500 WB 
Alexa 
Fluor 488 
mouse IgG donkey Invitrogen 1:500 IF 
 
Table 3. Information of antibodies used in Chapter 2 






Synthetic oligonucleotides were synthesized by the Integrated DNA Technologies. Sanger 
sequencing was performed at Genetic Resources Core Facility of Johns Hopkins University 
School of Medicine  
Purpose  Sequence Template 
Verify R1205H 




















Verify the 5’ insertion 
within the backbone 
GAGCGCCGGAGTATAAATAGAG hsp70 promoter 
Verify the 3’ insertion 
within the backbone 
CCATTCATCAGTTCCATAGG SV 40 intron 
 




Statistical significance was determined by one-way Analysis of variance (ANOVA) and 
Bonferroni posttest for comparison among multiple groups of more than three, or a two-
tailed nonpaired Student t-test for comparison of two groups (control and test) unless 





Generation of PD-associated EIF4G1 mutations knock-in cell line for functional 
study of the mutations 
Introduction 
The EIF4G1 gene, located on chromosome 3q27.1, encodes 1599 amino acids 
eukaryotic translation initiation factor 4G1 (eIF4G1) (Yan and Rhoads 1995). The function 
of eIF4G1 has been well characterized. eIF4G1 interacts with many initiation factors 
including eIF4E, eIF4A, eIF4B, eIF3, PABP, and some other unknown proteins serving as 
a scaffold protein in the initiation complex (Jackson, Hellen et al. 2010). The initiation 
complex helps the loading of the ribosome on the mRNA, which is a rate-limiting step for 
protein synthesis. Protein synthesis is the key process of protein homeostasis, and it is 
influencing critical cellular activities including metabolism, stress response, cell cycle, and 
cell death.  
Most of the disease cases in which eIF4G1 plays a role are cancer-related (Deng, 
Wu et al. 2015). eIF4G1 was reported overexpressed in 30% of a particular lung cancer 
and 80% of inflammatory breast cancer (Bauer, Diesinger et al. 2001, Silvera, Arju et al. 
2009). Also, patients with higher eIF4G1 level were found associated with shorter survival 
time in nasopharyngeal carcinoma (Tu, Liu et al. 2010). PD and cancer are seemingly 
unrelated, but it was raised decades ago that PD patients are protected from certain type of 
cancers, and many epidemiological studies suggest a negative correlation between PD and 
cancer (Strongosky, Farrer et al. 2008). This link between PD and cancer indicates the 
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hypothesis that genetic background that can protect an individual from cancer may 
predispose the one for PD (West, Dawson et al. 2005). Several genes later identified as 
PD-associated were studied in cancer research. For instance, parkin and PINK1 seem to be 
tumor suppressor genes, while DJ-1 was initially isolated in the screen for oncogene (West, 
Dawson et al. 2005). As EIF4G1 was identified as a potential PD gene, its role in cancer 
may provide insight into the mechanism of the neurodegeneration caused by EIF4G1 
mutations. 
The EIF4G1 mutations, suggested as PD-associated, had never been identified 
before, so little was known about how the mutations could affect the functions of eIF4G1. 
The original paper that reported the mutations did a few biochemical studies showing that 
the mutations hampered the interaction between eIF4G1 and other initiation components 
(Chartier-Harlin, Dachsel et al. 2011). For instance, R1205H reduced eIF4G1 binding with 
eIF4E, and A502V was shown to perturb the interaction between eIF4G1 and eIF4E. Since 
the main functions of eIF4G1 are mRNA translation initiation related, we started to study 
if the eIF4G1 mutants affect protein synthesis, and how they change the translation 
initiation. We used the transient transfection system by transfecting SH-SY5Y cells with 
V5-tagged WT-EIF4G1, RH-EIF4G1, and AV-EIF4G1, although we found by V5 
immunoblotting, expression of transfected eIF4G1 was confirmed, from eIF4G1 
immunoblotting, it was hard to see the obvious overexpression of eIF4G1 (Figure 14). 
Transfected mutant eIF4G1 taking an unclear portion of the overall eIF4G1 pool made the 
results of this experiment inconsistent and highly dependent on transfection efficiency. We 
assumed it was because the endogenous eIF4G1 was abundantly expressed and the overall 
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eIF4G1 protein amount was highly regulated, it was hard to induce strong exogenous 
eIF4G1 expression. Those data indicated a EIF4G1 mutation knock-in cells might be a 
better model. We then decided to generate the RH-EIF4G1 and AV-EIF4G1 knock-in cell 
lines by using the CRISPR/Cas system. 
The CRISPR/Cas9 genomic engineering technology was developed from the RNA-
based adaptive immune system in bacteria and archaea (Deveau, Garneau et al. 2010, 
Horvath and Barrangou 2010, Bhaya, Davison et al. 2011, Makarova, Haft et al. 2011). 
The best characterized type II CRISPR system from Streptococcus pyogenes, consists of 
the nuclease CRISPR-associated protein 9 (Cas9), the guide RNAs encoded CRISPR 
RNAs (crRNAs) and the required auxiliary trans-activating crRNA (tracrRNA) (Garneau, 
Dupuis et al. 2010, Sapranauskas, Gasiunas et al. 2011, Gasiunas, Barrangou et al. 2012, 
Jinek, Chylinski et al. 2012, Magadan, Dupuis et al. 2012). The guide RNA contains a 20-
nt sequence which determines the sequence specificity (Jinek, Chylinski et al. 2012). 
Besides complementary to the guide RNA, the target must have the protospacer adjacent 
motif (PAM) sequence, a 3-bp NGG motif following the 20-nt sequence (Jinek, Chylinski 
et al. 2012). By optimizing the codon of Cas9 and RNA components and fusing the crRNA 
and tracrRNA together to create a chimeric, single-guide RNA (sgRNA), the CRIPR/Cas9 
system can be implemented in various organisms (Cho, Kim et al. 2013, Cong, Ran et al. 
2013, Jinek, East et al. 2013, Mali, Yang et al. 2013). Just by altering the guide RNA 
sequence in sgRNA, the system can be used to target theoretically any 20-nt plus NGG 
genomic locus to make a DNA double-stranded break (DSB). Once a DSB is made by Cas9, 
either one of the two major pathways for DNA damage repair will initiate: the error-prone 
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non-homologous end joining (NHEJ) or the high-fidelity homology-directed repair 
pathway (HDR) (Cho, Kim et al. 2013, Cong, Ran et al. 2013, Jinek, East et al. 2013, Mali, 
Yang et al. 2013). NHEJ process will result in insertion/deletion (indel) mutations which 
can be harnessed to mediate gene knock-out (Perez, Wang et al. 2008). Given different 
repair templates, HDR can be leveraged to make gene knock-in.  
We have successfully generated the RH-EIF4G1 and AV-EIF4G1 knock-in 
SHSY5Y cell lines. And we have obtained consistent results from these cell lines. Both 
mutations resulted in reduced protein synthesis, and they affected both cap-dependent and 
cap-independent mRNA translation.   
 
Figure 14. Overexpression of eIF4G1 was hardly seen in eIF4G1 expressing plasmids 
transient transfection of SH-SY5Y cells. 
Representative Immunoblots showing indicated protein level. Each lane represents the cell 





sgRNA target selection and repair template ssODN design for generating knock-in 
cell lines 
Using plasmid-based donor repair templates with longer than 500-bp homologous 
arms flanking the alteration sites is the traditional way to generate knock-in cells (Thomas, 
Folger et al. 1986, Hasty, Rivera-Perez et al. 1991). The method is good for inserting large 
fragments like fluorescent proteins or antibiotic resistance markers. More recently, for 
short modifications, using single-stranded DNA oligonucleotides (ssODNs) containing 50 
~ 100-nt homologous arm on each side flanking the alteration site has been developed as 
an effective and simple method (Chen, Pruett-Miller et al. 2011). 
To make EIF4G1 RH and AV point mutation knock-in cell lines, we chose to use 
the ssODNs as the repair template. For sgRNA design, we used the genomic sequence 
within 100-base pair proximity to the mutation site as the input. Then we used the online 
CRISPR design tool (http://tools.genome-engineering.org) provided by Feng Zhang’s lab 
to generate a list of potential targeting sequences based on our input. The website provided 
computationally predicted off-target sites for each potential target ranked by the quantity 
and possibility of the predicted off-target sites (Ran, Hsu et al. 2013).  Ideally, we want to 
choose the guide RNAs with as less off-target sites as possible. Based on the previous 
report, single-base correction rates drop as the distance between the modification site and 
DSB increases (Elliott, Richardson et al. 1998). As the Cas9 cleavage site is ~3-bp 
upstream of PAM, we want to select the guide RNA with targeting site locates as close as 
possible to the mutation site or even overlaps optimally. So we found one guide RNA with 
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a high off-target score of 81 (the higher the score, the less off-target sites, with 100 as the 
highest and 0 as the lowest, and above 50 as acceptable) and targeting site overlapping the 
mutation for RH knock-in.  For AV knock-in, we found one sgRNA with targeting site 
overlapping the mutation, but its off-target score was relatively low as 64. So we added a 
second guide that does not overlap but has a score of 75 (Figure 15). We knew if the sgRNA 
targeting site on the genome remained intact after the repair template was used, a second 
cut could occur in the same location. So we designed a silent mutation at the PAM NGG 
site. Then we included 70nt homologous arm each side flanking the double stranded break 
for the rest of the ssODNs.  
sgRNA construction and functional test of the knock-in system in HEK293 cells 
For construction and delivery of CRISPR/Cas9 system with designed 20-nt guide 
RNA sequence, we chose one of the series of sgRNA expression constructs developed by 
Zhang lab, the one composed of coding sequence of Cas9, an invariant sgRNA scaffold, 
cloning site for specific designed sequence, 2A-GFP for selection and other expression and 
cloning elements, PX458. The 20-nt guide sequences were synthesized as single-stranded 
DNA oligos and annealed and ligated into the plasmid. The ssODNs were synthesized as 
4 nmol ultramers. (Integrated DNA Technologies) 
To perform functional validation of sgRNAs, we transfected HEK 293 cells with 
guide RNA expressing pSpCas9(BB)-2A-GFP plasmid with or without the ssODN repair 
template (the sense or the antisense can be considered as independent). 24 hours after 
transfection, we confirmed the efficiency of the transfection by checking the GFP 
expression under the microscope (Figure 16). 48 hours after transfection, we collected the 
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cells to examine if the system was functional and how the efficiency was. If the sgRNA 
works, it can induce a genomic inversion or deletion (indel) mutation. Indel mutations can 
be detected by SURVEYOR nuclease assay. We saw the desired cleavage band and 
estimated the efficiency ranging from 10% to 30 % (Figure 17).  
To test the efficiency of the repair template, we performed restriction-fragment 
length polymorphism (RFLP) analysis on RH template transfected cells and Sanger 
sequencing on AV template transfected cells (Ran, Hsu et al. 2013). Basically, if the G>A 
mutation of R1205H was successfully made, the recognition site “TGCA” of the restriction 
enzyme HpyCH4V would be present. After PCR amplifying the genomic region covering 
the homology donor region, the DNA fragment was subject to restriction enzyme digest. 
By quantification of the digested DNA fragment, the efficiencies of the knock-in 
combination were 5% for the sense ssODN and 2% for the antisense (Figure 18). However, 
AV mutation does not naturally create a restriction enzyme recognition site, we performed 
Sanger sequencing of 25 clones of AV1 sgRNA + ssODN sense and AV2 sgRNA + ssODN 
antisense. Both combinations worked and estimated efficiencies were 12% and 4% 





Figure 15. Diagram of the design of the sgRNAs and ssODNs. 
Light blue indicates the targeting sequences of sgRNAs on the genome, green indicates the 
sequences of the PAMs, dark blue narrow triangle points the predicted double-stranded 




Figure 16. Fluorescence images showing the transfection efficiency and the expression 
of the constructs. 
HEK Cells in one well of the 12-well plate was transfected with indicated single-guide 
RNA expressing pSpCas9(BB)-2A-GFP plasmid with or without ssODNs. ODNF: sense 





Figure 17. Results of functional test of sgRNAs 
(A). Schematic of the SURVEYOR assay used to test the function of sgRNAs. (B) 
SURVEYOR gel shows the indel percentage of RH sgRNA +/- ssODNs treated cells. (C) 






pX458 is the backbone plasmid without sgRNA. sgRNA-1 and sgRNA-2 represent the 
same targeting sequence but different clones.  
 
 





(A) Schematic shows the designed sgRNA, genomic targeting site, and ssODN. (B) HEK 
cells were transfected with RH sgRNA targeting plasmid and repair template ssODNs. The 
restriction enzyme targeting site was introduced if the repair template was incorporated. 
PCR-amplified DNA fragment flanking the mutation site was digested by the indicated 
enzyme. Digested bands indicate the occurrence of homology-directed repair (HDR) events. 
ssODNs, oriented in either sense (ODNF) or anti-sense (ODNR) can be used independently 




Figure 19. Results of functional test of HDR of AV sgRNA + ssODNs in HEK cells 
PCR amplification of the target region on the genome from AV sgRNA + ssODNs treated 
cells, amplicons were TA cloned into the sequencing plasmids. 25 clones were subjected 
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to Sanger sequencing to assess the HDR-mediated targeting efficiency. Representative 
chromatogram of AV1 and sequence alignment of AV2 are shown.  
ssODN repair template and knock-in cell line generation procedure optimization  
Then we moved forward with the sgRNA and ssODN to transfect the human 
embryonic stem cells (hESCs). After the transfection, we did single cell isolation and 
genotyping. To our surprise, we did not identify a positive RH knock-in clone by RFLP, 
but when we treated the same PCR products with the restriction enzyme that could cut the 
wild type sequence but not any altered sequence, we found 4 out of 50 samples could not 
be digested, this told us the gene editing happened, but there was no intended mutation 
(Figure 20). From the sequencing result of AV, we did not detect any intended mutation in 
300 clones treated with AV1 sgRNA + ssODN combination, but for AV2 sgRNA + ssODN, 
we detected the presence of the mixture peaks around our intended mutation from the 
chromatogram in 11 out of 200 clones. Further dissection of the sequence of the DNA 
samples of these 11 clones by TA cloning and plasmid sequencing, we found unwanted 
indel mutations in all the HDR events (Figure 21). It seemed like the HDR efficiency of 
AV1 sgRNA + ssODN was dramatically lower than AV2 sgRNA + ssODN in hESCs, 
though it was the opposite in HEK293 cells. Also, identification of unwanted indels 
together with intended mutation indicated that re-cut occurred at the edited site in AV2 
sgRNA + ssODN treated cells.  
We were aware that if the targeting sequence of sgRNA was unchanged after the 
integration of the repair template, a second cut could occur in the same location. For RH 
sgRNA and AV2 sgRNA, their binding sites was supposed to be altered after the HDR 
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because of the overlap between the targeting sites and the intended mutations, so it was 
unexpected to see indel in AV2 sgRNA + ssODN treated cells. We suspected that one 
nucleotide might be not sufficient to block the binding of sgRNA with the genomic DNA, 
so the second or more cleavages continued to happen until the NHEJ-mediated 
modification prevented the further cutting. So we assumed we had to induce a synonymous 
blocking mutation to prevent the further editing and the blocking mutation had to be 
sufficient enough. We knew the NGG protospacer adjacent motif (PAM) is the required 
element for sgRNA-mediated binding, so we decided to introduce a silent mutation in the 
PAM sequence of our sgRNA targeting sites. We also realized that the overall HDR 
efficiency was very low, and we need to use the powerful RFLP instead of Sanger sequence 
to genotype the AV clones. Since we could not identify a restriction enzyme site after the 
intended mutation was created, we had to find if we could create a restriction enzyme site 
close to the mutation site, at the same time the sequence remained synonymous. We found 
for AV1 sgRNA, it was hard to find an available synonymous restriction enzyme site 
between the intended mutation and PAM, and the HDR efficiency of AV1sgRNA + ssODN 
was suggested low. So we re-designed the repair template ssODNs for RH and AV 
respectively, with the intended mutation, the blocking mutation on the PAM, and the 
genotyping-required restriction enzyme mutation (Figure 22). And we also chose to use 
SH-SY5Y cells, a neuroblastoma cell line, to optimize the design and procedure. 
To overcome the low efficiency problem of HDR, we also applied another 
improvement. It was reported that by targeting DNA ligase IV, a critical enzyme for NHEJ, 
using the small molecule inhibitor Scr7, the efficiency of HDR can be increased 
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(Maruyama, Dougan et al. 2015). Another group did a screening for the small molecules 
that boost HDR, and they found L-755,507, known as a potent and selective β3 adrenergic 
receptor partial agonist (Yu, Liu et al. 2015). We tested two drugs suggested in these 
studies in the RH sgRNA + ssODN transfected SH-SY5Y cells, we saw a subtle increase 
of the digested bands in Scr7 (1M) and L-755,507 (1M) treated cells (Figure 23A). After 
the transfection and drug treatment, we used the fluorescence sorting to select the GFP- 
positive cells, so only the cells with the construct transfected and expressed were enriched. 
We then cultured the sorted cells as a whole until they reached stable growth. At the first 
transfer of the cells, we did RFLP with the half of the cells to see if there were any digested 
bands which indicated there were knock-in cells in the population. We detected the 
digested band in RHsg + ssODN transfected and Scr7 treated cells, so we were confident 
that there were knock-in cells in this population, this time the L-755,507 treated cells 
showed unexpected bands, so we stayed with the Scr7 treated cells only (Figure 23B). Then 
we did single cell isolation by serial dilution of the cells into 384 wells. We kept monitoring 
the wells and identified 200 single cell developed colonies. Two weeks after we plated the 
cells, the cell number of single clones reached about 5000, then we collected half of the 
cells for genotyping and transferred the other half to larger wells to keep the clones. From 
the first round genotyping by RFLP, we found 3 samples out of 84 showing the small size 
band, indicating these three could be the knock-in clones (Figure 24). We repeated the 
digestion and did TA clone of the PCR products into plasmids, following by Sanger 
sequencing of 30 independent clones per sample to identify all alleles within the sample. 
We got one sample with one wild type allele and the other allele containing both the 
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intended mutation and the blocking mutation, and the wild type versus mutation allele ratio 
is approximately 1:1.  
Then we repeated the same procedure with AVsgRNA + ssODN. We transfected 
the cells and sorted for GFP after 48 hours. Grew the cells until they were stable and used 
the half of the cells for population genotyping. After we confirmed there were knock-in 
cells in the population we did the single cell isolation and genotyping of the individual 
clone. This time, instead of purifying and digesting PCR products of 100 clones, we 
grouped PCR products of 6 samples into one sample, purified and digested the grouped 
samples, ran the reaction on the agarose gel. Because based our previous experience, the 
minimum detectable DNA amount on 2% agarose gel for low molecular size band ranges 
from 50 to 100 ng, if there was a positive clone out of 6 sample, as long as we loaded more 
than 600ng of DNA, we should be able to detect the digested band. So we identified 3 
grouped samples with the positive bands and we further checked the 18 samples of 
individual clone from these 3 groups (Figure 25). 4 clones showed the digested bands, and 
we verified these 4 by cloning the PCR products into the plasmids and Sanger sequencing 
30 independent bacterial clones. We found one cell line clone with one wild type allele and 
one edited allele containing the intended mutation, the blocking mutation, and the 
restriction enzyme mutation, and the allele ratio was about 1:1. So far we have successfully 







Figure 20. Results of genotyping of RH single clones by RFLP 
Amplicons of DNA fragment flanking the targeting site of the genome of single clones 
were subjected to restriction enzyme digestion. HpyCH4V recognizes the predicted 
mutation sequence, Fspi recognizes the wild-type genomic sequence. gBlock is the 
synthesized DNA double strand fragment which has the same sequence of the PCR 







Figure 21. Results of genotyping of AV single clones by Sanger sequencing of PCR 
products. 
(A) Representative of chromatogram of Sanger sequencing of PCR product. Amplicons of 
DNA fragment flanking the targeting site of genome of single clones were directly 
subjected to Sanger sequencing. (B) Representative sequence alignment of sequencing 
results of the plasmid with PCR amplicon. The clones showing mixed chromatogram was 
followed by TA cloning and sequencing to reveal all the sequence of all the alleles.  











Figure 22. Optimization of ssODNs repair template for RH and AV 
Diagram of the new design of the repair template ssODNs, and respective genome DNA 
sequences and amino acid sequences. Light blue indicates the targeting sequences of 
sgRNAs on the genome, green indicates the sequences of the PAMs, dark blue narrow 
triangle points the predicted double-stranded break site, red indicates the mutation sites, 
including the intended mutation, the silent blocking mutation on the PAM, and the 




Figure 23. The NHEJ inhibitor Scr7 increases the HDR efficiency. 
(A). Different wells of cells were treated with RH sgRNA only (lane 1), RH sgRNA + 
ssODN (lane 2), RH sgRNA + ssODN + DMSO (lane 3), RH sgRNA + ssODN + Scr7 
solved in DMSO of indicated concentration (lane 4-7), and RH sgRNA + ssODN + 
L755,507 solved in DMSO of indicated concentration (lane 8-10). Amplicons of DNA 
fragment flanking the targeting site of the genome of each sample and gBlock (positive 
control) were subjected to restriction enzyme digestion, and HDR efficiency was analyzed. 





drug with the concentration showing highest HDR efficiency at panel A. The samples were 
subjected to restriction enzyme digestion.  
 
 
Figure 24. Identify the RH knock-in clones from genotyping by RFLP 
(A) Amplicons of DNA fragment flanking the RH sgRNA targeting site of the genome of 
single clones were subjected to restriction enzyme HpyCH4V digestion for genotyping. (B) 
Representative chromatogram of Sanger sequencing. Positive clones were confirmed by 






Figure 25. Identify the AV knock-in clones from genotyping by RFLP and confirm by 
Sanger sequencing. 
(A) Amplicons of DNA fragment flanking the AV sgRNA targeting site of the genome 





(B) Representative chromatogram of Sanger sequencing. Positive clones were 
confirmed by TA cloning of the amplicon to the plasmid and Sanger sequencing.  
Effect of EIF4G1 PD-associated mutations on protein synthesis  
To see if mutations of EIF4G1 affect global protein synthesis, we chose to use 
isotope pulse labeling assay to measure the protein synthesis rate. We plated WT, R1205H 
knock-in, and A502V knock-in cells at sub-confluent status, 24 hour later cells were 
incubated in cell culture medium containing radioactive 35S‐Met/Cys for an hour. Then 
the cells were lysed, and the protein in part of the lysate was used for liquid scintillation 
counting, the protein in the rest of the lysate was subject to SDS-PAGE and transferred to 
a nitrocellulose membrane for phosphorscreen exposure. Radioactive signals in the mutant 
cells were significantly lower than that in the wild type cells, suggesting a decrease in 
protein synthesis rate caused by EIF4G1 mutations. And SDS-PAGE analysis indicated 
synthesis rates of proteins in a large range of molecular sizes were decreased (Figure 26). 
Since our transgenic flies showed the PD-like phenotypes, we then wanted to know if the 
mutations could cause global translation down in the transgenic flies. We crossed the UAS-
WT-EIF4G1, UAS-RH-EIF4G1, and UAS-AV-EIF4G1 flies with ELAV-GAL4 flies, and 
collected flies with transgene expressed in the whole brain. Then the flies were transferred 
to 35S‐Met/Cys labeled food for 24 hours. The fly heads were harvested and lysed for 
scintillation counting and SDS-PAGE. Consistent with the observations in the knock-in 
cells, EIF4G1 mutant flies showed decreased protein synthesis rate compared with WT-
EIF4G1 transgenic flies (Figure 27). However, we saw similar level of global translation 
of mutant flies as the Control flies. But we did find the mutant flies showed impaired 
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phenotypes when compared with the Control flies. We thought the mutant eIF4G1 may 
affect the subset of the transcripts but the endogenous fly eIF4G compensated the global 
translation rate.  
eIF4G1 is involved in both cap-dependent and cap-independent translation. To test 
if mutations of EIF4G1 can affect either or both type of translation initiation, we used a 
bicistronic reporter assay. As the schematic diagram shows, the bicistronic reporter is 
composed of a FLAG readout to monitor cap-dependent translation followed by an IRES 
site with c-Myc readout to monitor cap-independent translation from the same transcript. 
We transfected the WT, RH, and AV cells with the reporter DNA and harvested cells to 
analysis the reporter expression. We found both cap-dependent and cap-independent 
translation were dramatically decreased in AV knock-in cells. The cap-dependent 
translation in RH cells was slightly decreased, but cap-independent was not. This data 
reflected the phenotypes we found in the transgenic flies that though both mutations caused 







Figure 26. Reduced global translation in RH and AV knock-in cell lines. 
Cells in one well of 6-well plate were incubated with 100 Ci of 35S-Met/Cys for one hour. 
Half of the cell lysate was subjected to SDS-PAGE and the other half was subjected to 
methanol precipitation for liquid scintillation counting. (A) Protein de novo synthesis rate, 
indicated by the 35S-Met/Cys incorporation measured by liquid scintillation counting, was 
significantly reduced in RH and AV knock-in cells (ANOVA, Tukey's post hoc test, 
**p<0.01, *p<0.05, n=3). (B) Autoradiography from lysates revealed a widespread 






Figure 27. Reduced global translation in RH and AV transgenic flies. 
Cohort of 30 flies per vial of 3 vials of each genotype were fed normal food mixed with 
100 Ci of 35S-Met/Cys for 24 hours. Fly heads extracts were subjected to SDS-PAGE and 
scintillation counting. (A) Protein de novo synthesis rate was significantly reduced in RH 
and AV transgenic flies (ANOVA, Tukey's post hoc test, *p<0.05, n=3 vials of 30 flies per 
vial). (B) Autoradiography from lysates revealed a widespread increase in 35S-Met/Cys-






Figure 28. AV mutation reduces both cap-dependent and cap-independent translation, 






(A) Schematic representation of the bicistronic reporter used. (B) Representative 
immunoblots of bi-cistronic reporter assay. Bicistronic reporter was transfected into the 
WT, RH, AV eIF4G1 knock-in SH-SY5Y cells. After 24hours, cells were collected and 
lyzed, fractionated by SDS-PAGE, and analyzed by immunoblotting with the indicated 
antibodies. (C) Quantification of the protein level shows AV mutation reduces both cap-
dependent and cap-independent translation, while RH mutation slightly reduces cap-





As EIF4G1 is ubiquitously and abundantly expressed, we realized it was hard to 
dissect the effects caused by transfected mutant EIF4G1 in transient transfection system 
(Figure 14). Thus we have generated EIF4G1 mutation knock-in cell lines using the 
genomic editing technology CRISPR/Cas9. When we started to apply this technology, it 
was less than a year after the first couple of papers just came out. While CRISPR/Cas9 had 
been reported extensively in genomic engineering to make knock down or knock out, 
generating knock-in organisms utilizing the Homology-Directed Repair remained 
inefficient (Yang, Wang et al. 2013, Platt, Chen et al. 2014, Dow, Fisher et al. 2015). There 
are a few explanations for the low efficiency of HDR editing. HDR occurs only during S 
and G2 phase, less frequently than NHEJ which could occur at any phase (Lieber 2010). 
And the nuclease activity of CRISPR/Cas9 is considered very robust, so continuous editing 
could happen until the targeting site is largely altered (Wang, Yang et al. 2013, Canver, 
Bauer et al. 2014). When we were designing the first set of sgRNA and ssODN, we took 
into consideration that if the targeting site overlaps with the mutation site, the nucleotide 
change could potentially block the second cleavage (Figure 15). However, we found no 
positive R1205H knock-in clone by RFLP genotyping out of about 300 clones (Figure 20). 
By Sanger sequencing of around 300 clones of AVsgRNA edited cells, we identified the 
intended mutation but companied by undesired indels at several nucleotides distance 
(Figure 21).  We concluded that in our case, single nucleotide in the targeting site was not 
sufficient to block the further editing. 
80 
 
So we came up with the solution that the continuous cutting could be prevented 
only if the required PAM sequence is altered. This solution was also mentioned in several 
later published papers (Hsu, Lander et al. 2014, Paquet, Kwart et al. 2016). Besides 
designing a silent blocking mutation of the NGG sequence in our ssODNs, we also 
introduce a synonymous nucleotide change that created a novel restriction enzyme site for 
efficient genotyping purpose (Figure 22). To increase the overall efficiency of getting the 
knock-in clones, we treated the cells with small molecule Scr7, a NHEJ inhibitor (Figure 
23). We also applied fluorescence cell sorting to select the cells with Cas9 expressed. 
Instead of performing single cell isolation right after the sorting, we culture the sorted cells 
as a whole until they reached stable growth to increase the survival chance of edited cells. 
And before doing the labor intensive single cell isolation, we genotyped the whole cell 
population to make sure there were knock-in cells existing and figure out their percentage. 
We optimized and streamlined the procedure so we were able to generate a knock-in cell 
line within one month. Both RH and AV knock-in cell lines we got were heterozygous. 
Since EIF4G1 mutation was identified as autosomal dominant, we did not proceed to make 
a homozygous line.  
As the involvement of eIF4G1in mRNA translation initiation has been well 
characterized, the first question we wanted to know about the mutations was if they could 
affect the protein synthesis. 35S-Met/Cys metabolic labeling in the knock-in cells showed 
the global translation was decreased in mutant cells compared with the wild type cells 
(Figure 26). It was consistent in transgenic flies that mutations were associated with 
decreased protein synthesis rate when compared with WT-eIF4G1 expressing flies (Figure 
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27). These data suggested that EIF4G1 mutations caused mRNA translation repression, 
and reduced protein synthesis was associated with neurodegeneration. This finding was a 
surprise to us, but was not totally unexpected. Our lab reported that increased 
phosphorylation of ribosomal protein s15 by pathogenic G2019S LRRK2 elevates global 
protein synthesis and causes neurotoxicity (Martin, Kim et al. 2014). But it was also 
reported that sustained protein translation repression was associated with synaptic failure 
and neurodegeneration in prion-diseased mice (Moreno, Radford et al. 2012). Also, some 
other reports showed that decreased protein translation found in age-related 
neurodegeneration (Douglas and Dillin 2010). It can be explained by that the balance of 
protein level is crucial for cell survival, either too much or too little is detrimental. Another 
reason could be different genes regulate different subsets of mRNA transcripts. And 
survival-required expression levels of different mRNAs are different. In the following 
studies of phosphorylation of rps15 by LRRK2, our lab did a genome-wide translation 
profiling with G2019S LRRK2, and we found some particular subsets of mRNAs were 
sensitive to LRRK2 mutation. There were studies about the preference of eIF4G1 on 
translation initiation of mRNA with particular sequence features. It was reported that in 
breast cancer cell line, depletion of eIF4G1 would affect the mRNA with multiple upstream 
open reading frames (Ramirez-Valle, Braunstein et al. 2008). There was also a study about 
that in C.elegans, eIF4G1 mediated somatic maintenance by regulating mRNA with 
longer-than-average ORF length (Rogers, Chen et al. 2011). In a recently published paper, 
eIF4G1 was suggested being required for efficient translation of mRNAs with structured 
5’ UTR (Liew, Assmann et al. 2014).  
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And we also dissected the effect of the mutations on cap-dependent and cap-
independent translation. We found cap-dependent translation was slightly decreased in RH 
knock-in cells, but cap-independent translation did not. Whereas in AV knock-in cells, both 
cap-dependent and cap-independent translation were prominently decreased (Figure 28). 
This finding was consistent with the PD-like phenotypes in the trangenic flies that AV 
transgenic flies showed more severe symptoms. But we coud not distinguish if the AV 
mutation abolished the protein function to a larger extend or it affected a wider range of 
transcripts than the RH mutation. Additional biochemical studies are required to study the 
effects of the mutations on protein translation in more granular level. The knock-in cell 
lines will provide a stable platform supporting these studies. And we can also apply the 
same procedure to generate knock-in embryonic stem cells, and differentiate them to 














Materials and Methods 
Generation of EIF4G1 RH/AV knock-in SH-SY5Y cell lines 
Design sgRNA and ssODNs 
 
EIF4G1 genomic sequence, Chromosome 3: 184,314,495-184,335,358 forward 
strand. GRCh38:CM000665.2, was acquired from Ensembl. 250 base upstream and 250 
bases downstream of the mutation site was used as the input in the online CRISPR Design 
Tool (http://tools.genome-engineering.org) for generating a list of target sites ranked by 
off-target scores. The scores and the distance-to-mutation were considered for picking the 
sgRNA sequences. Due to the requirement of human U6 promoter to have a ‘G’ base at the 
transcription start site. A 20bp genome target starting with the base ‘G’ is preferred, but if 
the more important criteria can be met by the targeting sequence starting with other bases, 
an additional ‘G’ could be added to the front of guide oligo sequence. sgRNA target 
sequence was put into the following format and synthesized as DNA oligos at Integrated 
DNA Technologies (IDT).  
5’ – CACCGNNNNNNNNNNNNNNNNNNN          – 3’ 
3’ –            CNNNNNNNNNNNNNNNNNNNCAAA – 5’ 
EIF4G1 genomic sequence 100 bases upstream and downstream of the mutation 
site was selected for ssODN design. The point mutation nucleotide was changed. The 
synonymous mutation was made at one of the G sites of NGG PAM. And silent mutation 
for creating a novel restriction enzyme targeting site around mutation site was identified 
by the online tool: http://resitefinder.appspot.com/ Both the sense and antisense ssODNs 
were ordered as 4 nM Ultramer® at IDT.  
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Generation of sgRNA expression constructs 
 
We used the plasmid-based cloning methods as previously described. 
1. The sense and antisense guide oligos were phosphorylated and annealed as following: 1 
μL sense oligo (100μM), 1 μL antisense oligo (100μM), 1 μL 10X T4 Ligation Buffer 
(NEB) 6.5 μL ddH2O, 0.5 μL T4 PNK (NEB) were mixed and annealed in a thermocycler 
using the following parameters: 37C 30 min, 95C 5 min and then ramp down to 25C at 
5C/min. 
2. Single-step digestion-ligation.  
X μL PX458 (SpCas9(BB)-2A-GFP) vector (100ng), 2 μL phosphorylated and annealed 
oligo duplex from step 1 (1:250 dilution), 2 μL 10X Tango buffer (Thermo Scientific), 1 
μL DTT (10mM to a final concentration of 1mM, Fermentas), 1 μL ATP (10mM to a final 
concentration of 1mM, New England BioLabs), 1 μL FastDigest BbsI (Thermo Fisher 
Fermentas), 0.5 μL T7 DNA ligase (New England BioLabs), Y μL ddH2O, 20 μL total 
were mixed, the ligation reaction was incubated in a thermocycler: 37 C 5 min, 23 C 5 min 
for 6 cycles, 4 C hold until next step. 
3. Treat with PlasmidSafe exonuclease to prevent unwanted recombination products:  
11 μL ligation reaction from step 2, 1.5 μL 10X PlasmidSafe Buffer (Epicentre), 1.5 μL 
10mM ATP (Epicentre), 1 μL PlasmidSafe exonuclease (Epicentre), 15 μL total were 
mixed, and the reaction was incubated at 37C for 30 min.  
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4. Transformation with 1-2 μL of the final product into STBL3 competent cells. Pick the 
colonies and sequence verify the clones.  
Cell Culture and Transfection 
 
The human neuroblastoma SH-SY5Y cells were cultured in Dulbecco's modified 
Eagle's medium (DMEM) containing 10% fetal bovine serum and 100U/ml of 
penicillin/streptomycin antibiotics and were grown at 37°C, 7% CO2, and 90% humidity. 
Cells were plated at sub confluent in 6 well plate 24 hours before transfection. Suspended 
the ssODNs in ddH2O to a final concentration of 10 uM. 500 ng of PX458(sgRNA) was 
premixed with 1 μL of the ssODN template. Transfections was performed using X-
tremeGENE™ transfection reagent according to the manufacturer's instructions (Roche). 
At the same time, Scr7 (Excess Bioscience) was added to the cell culture medium at the 
end concentration of 1uM. 48 hours after transfection, cells were harvested for 
fluorescence-activated cell sorting (FACS). GFP-positive cells were selected, half were 
cultured, and the rest were for the functional test of genomic editing.  
Gene editing efficiency test by the SURVEYOR nuclease assay, the restriction-
fragment length polymorphism (RFLP) analysis, and Sanger sequencing 
 
Cells were harvested and lysed in the QuickExtract solution (Epicentre) for 
genomic DNA extraction according to the manufacturer’s instructions. The final 
concentration of extracted DNA solution was normalized to 100 ng/ μL with ddH2O. PCR 
reaction was performed using the high-fidelity polymerase, Herculase II fusion polymerase 
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(Agilent). Primers were designed to amplify 500 base pair DNA fragment around the 
sgRNA targeting site.  
PCR reaction mix was optimized as following:  
Component Amount(μL) Final concentration 
Herculase II PCR buffer, 5× 
 
10 1x 




Fwd primer, 10uM 1.25 0.25uM 
Rev primer, 10uM 1.25 0.25uM 
DMSO 1 2% 




DNA template 2 4ng/ μL 
ddH2O 32.5  
Total 50  
 
The cycling conditions were also optimized as: 
Cycle number Denature Anneal Extend 
1 95 C, 2 min   
35  56 C, 30 s 72 C, 30 s 
1   72 C, 3 min 
 
5 μL PCR products were used to confirm the experiment worked and the rest was purified 
with the QIAQuick PCR purification kit (Qiagen).  
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DNA heteroduplex formation was set up as 2  of Taq PCR buffer (NEB), 10x, 
18  of Normalized PCR product, 20 ng/. The annealing reaction was set up the same 
as the protocol. Then the product was digested by Surveyor® Mutation Detection Kits (IDT) 
following the manufacturer’s instructions. The digestion products were ran at the 2% 
(wt.vol) agarose gel added with ethidium bromide. The gel was imaged and the intensities 
of the bands were quantified by ImageJ.  
For restriction-fragment length polymorphism (RFLP) analysis, starting with 
genomic DNA extraction, the following steps were the same before enzyme digestion. The 
digestion reactions were set up according to the corresponding specific enzyme.  
For Sanger sequencing, repeat same steps from DNA extraction to PCR product 
purification. Then the PCR products were cloned into the plasmid for sequencing using the 
Zero Blunt® TOPO® PCR Cloning Kit for Sequencing (ThermoFisher Scientific) 
following the manufacturer’s protocols.  
Single cell isolation  
 
Passaged the cells for at least two times after cell sorting until the cells were 
growing stable. Dissociated the cells and pipetted the cell to ensure single cells. Count the 
cell numbers and performed 10-fold serial dilution to a final concentration of 1 cell per 200 
. Examined the cell concentration at an intermediate stage, adjusted the dilution volume 
if necessary. Prepared three 96-well plates for each transfection combination. Use 
mtichannel pipette to add 200  of cell solution to each well. Monitor the colonies for 
single cell clonal appearance. Visible clones can be found one week after plating. Allow 
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the cells to grow for additional one week or two and monitor the confluence. When the 
cells are more than 80% confluent, dissociate the cells, and use 80% of total cells for 
genotyping and plate the remaining cells into the replica wells.   
De Novo Protein Synthesis measurement by 35S-methionine/cysteine incorporation 
 
SHSY5Y cells were plated at 40%-50% confluent in 6-well plate one night in 
advance. One milliliter of culture medium was pipetted out into a tube from each well. 35S-
methionine/cysteine (PerkinElmer) was added to the medium collection as 100 uCi per 
well. Then the culture medium mixed with isotope was added back to each well. The plate 
was placed back into the incubator for one hour. Then took the plate out, removed the 
radioactive medium, washed the cells with cold PBS for two times. Cells were harvested 
and lysed in extraction buffer (1% NP-40, 50 mM Tris-HCl, 150 mM NaCl, 5 mM EGTA, 
protease inhibitor cocktail). Half of the lysate was processed through SDS-PAGE and 
transferred to nitrocellulose membrane. Total protein amount was visualized by Ponceau S 
dye (Sigma-Aldrich) staining. Radioactive signal was captured by incubating the 
membrane in the phosphor screen cassette for 24 hours. The other half of the lysate was 
concentrated by methanol/heparin protein precipitation. For every 100  of protein 
faction, add 1 of Heparin (100 mg/ml), and 400  methanol, mixed and span at top 
speed for 5 minutes. Removed the supernatant and dried the pellets in the air. Resuspended 
the pellets with 20 µl 8M Urea/150 mM Tris (pH 8.5). Added 10 μL of sample into the 
liquid scintillator, and analyzed the mixture in the Liquid Scintillation Counter. Used 2 μL 
of the sample to test protein concentration using BCA assay. The final result was the 
radioactive activity (reported as counts per minute) normalized by the total protein amount.  
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For protein synthesis measurement in flies, 35S-methionine/cysteine was 
incorporated into flies through feeding them with food-isotope mixture. Standard solid 
food was melt and distributed at 1ml per well, 24 hours later, the food was dry. 35S-
methionine/cysteine was diluted as 100 uCi per 100 μL ddH2O, then 100 μL of diluted 
isotope was added to the food. Waited for another 24 hours till the isotope was completely 
soaked into the food. 30 flies were transferred to the isotope-mixed food and fed for 24 
hours. Then the flies were moved to normal food for an hour. Flies were collected into the 
1.5ml tube and froze on the dry ice. Fly heads were separated by vortex for 30 seconds and 
picked manually into a new tube on the ice. Extraction buffer (1% NP-40, 50 mM Tris-
HCl, 150 mM NaCl, 5 mM EGTA, protease inhibitor cocktail) was added in the tube and 
fly heads were homogenized by a motor-driven pestle. Then the tissue was lysed on ice for 
30 minutes and centrifuged at 14,000 g for 30 min. The supernatant was collected and 
proceeded as the same method described above.  
Bicistronic reporter assay 
 
The bicistronic reporter construct (pCMV-BICEP 4, Sigma), expressing a single 
transcript induced by the CMV promoter, contains two eGFP open reading frames, one is 
N-terminal FLAG-tagged, the other is N-terminal c-Myc-tagged. Translation of the 
upstream FLAG-tagged GFP is cap-dependent, while the ribosome entry site (IRES) 
derived from the encephalomyo-carditis virus (EMCV) controls the translation of the 
downstream c-Myc-tagged GFP in a cap-independent manner. SH-SY5Y cells were plated 
in the 6-well plate at 40% confluent in the previous night. The following day, cells were 
transfected with 0.5 ug of the bicistronic reporter DNA per well using X-tremeGENE HP 
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transfection reagent (Roche).24 hr after transfection, cells were harvested and lysed in 
extraction buffer (1% NP-40, 50 mM Tris-HCl, 150 mM NaCl, 5 mM EGTA, protease 
inhibitor cocktail). The lysates were resolved on SDS-PAGE gel and subjected to 
immunoblot analysis.  
Materials 
 
Primer oligos and ssODNs 
 
Synthetic oligonucleotides were synthesized by the Integrated DNA Technologies. Sanger 
sequencing was performed at Genetic Resources Core Facility of Johns Hopkins University 
School of Medicine  



























































Table 5. Primers and ssODNs used in Chapter 3 
 
All the ssODNs are designed based on the EIF4G1 genomic sequence ENSG00000114867. 
The ssODNs listed above are the second batch design described in the result session, these 
were used in the successful generation of the knock-in cell line.  
Reagents 
 
All stock solutions for experiments in chapter 3 were prepared following the methods 
described in the Materials and Methods section in Chapter 2. Other reagents:  
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30% acrylamide/bis solution, 29:1 (3.3% C) (bio-rad). Restore Western blot stripping 
buffer (Thermo Scientific). Ponceau S solution (Sigma-Aldrich). Supersignal West Pico/ 
Femto chemiluminescent substrate (Thermo Scientific). BCA protein assays reagent 
(Pierce). DNA mini-/ maxi- prep kit (Qiagen). For information regarding components of 
protease inhibitors and sequence information of primers used in this chapter, refer to 
Materials and Methods section in Chapter 2. 
Antibodies 
 
Conjugant Antigen Species Supplier Titer Application 
N/A eIF4G1 rabbit Cell Signaling 1:1000 WB 
HRP -Actin mouse Sigma-Aldrich 1:10,00
0 
WB 
HRP V5 mouse Invitrogen 1:5000 WB 
HRP FLAG mouse Sigma-Aldrich 1:5,000 WB 
HRP c-Myc mouse Invitrogen 1:5000 WB 
HRP mouse IgG sheep GE Healthcare 1:2,500 WB 














Statistical significance was determined by one-way Analysis of variance (ANOVA) and 
Tukey's post hoc test for comparison among multiple groups of more than three, or a two-
tailed nonpaired Student t-test for comparison of two groups (control and test) unless 






Missense mutation c.3614G>A (p.R1205H) of EIF4G1 gene has been identified in 
autosomal dominant familial Parkinson disease cases (Chartier-Harlin, Dachsel et al. 2011). 
The c.1505C>T (p.Ala502Val) mutation was the most frequent substitution identified in 
some small families in the same study, and also suggested from an ancestral founder in the 
haplotype analysis. Following studies have also identified other variants (Figure 1), but the 
mutations of EIF4G1 gene seemed to be rare, and genetic studies were not enough to prove 
the mutations were causal (Deng, Wu et al. 2015). However, we believe the study of 
EIF4G1 mutations will help us understand better about PD pathogenesis, as eIF4G1 is 
crucial in protein translation and many studies have revealed that aberrant protein 
translation can lead to various neurological disorders, including neurodegenerative disease. 
To answer if and how the mutations of EIF4G1 could lead to Parkinson disease, we 
generated a transgenic Drosophila model and knock-in SH-SY5Y cell lines. We found that 
overexpression of RH-eIF4G1 and AV-eIF4G1 in dopaminergic neurons of the flies caused 
PD-like phenotypes, and mutant flies showed the less global translation than the WT-
eIF4G1 expressing flies, but the same as the control flies. With the abundant amount of 
endogenous eIF4G in the transgenic model, we cannot tell whether there was compensation 
effect or the mutations were dominant negative. Later we found both mutations suppressed 
the global protein synthesis in knock-in cells. 
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Development of transgenic Drosophila for EIF4G1-linked Parkinson’s disease 
modeling 
By employing the GAL4/UAS system, we have generated tissue-specific WT-
EIF4G1, R1205H-EIF4G1, and A502V-EIF4G1 transgenic flies. As the TH-GAL4 line, in 
which GAL4 is regulated under the promoter of Drosophila tyrosine hydroxylase (DTH) 
gene (Friggi-Grelin, Coulom et al. 2003), was already available in the Bloomington 
Drosophila Stock Center and proved to induce robust GAL4 expression specifically in 
dopaminergic neurons, our main effort was focused on optimizing the UAS line.  
As we wanted to compare overexpression of wild type versus mutants, the equal 
levels of protein expression across the transgenic lines were critical. And eIF4G1 is 
abundantly and ubiquitously expressed, so the transgene expression level must be high 
enough to overcome the effect of endogenous wild type protein. We have tried three 
different types of constructs for generating the lines. We started with the traditional P-
element induced transformation. As the “position effects” of random insertion of P-element 
into the chromatin, both the mRNA and protein levels of the transgene across the lines 
were largely varied (Figure 4, 5). It is accepted that if the P-element induced transformation 
lines are used, there should be at least two independent lines from each genotype expressing 
the similar level of the transgene. So to overcome the problem of the transgene expression 
variance, we switched to the site-specific integration system induced by the phiC31 
integrase (Groth, Fish et al. 2004), a bacteriophage isolated integrase that could mediate 
the unidirectional sequence-specific recombination between two DNA fragments, attB and 
attP (Figure 6). Konrad Basler’s group developed the host lines that have both attP site 
96 
 
and PhiC31 integrase engineered into the genome, so attB DNA constructs can be inserted 
at the known genomic location (Bischof, Maeda et al. 2007). However, we found although 
the transgene expression levels across the PhiC31 lines were equal, the absolute level was 
low compared with the P-element lines, so we had to find the new strategy that allowed us 
to have a broader range of transgene expression level. Rubin Gerald’s group modified the 
attB plasmid by adding the copy numbers of UAS from 5 to 10, 20, and 40 and developed 
the pJFRC plasmid series (Figure 7) (Pfeiffer, Ngo et al. 2010). We cloned the EIF4G1 
coding sequence into the pJFRC-10xUAS and pJFRC-20xUAS and received the lines 
expressing robust and equal levels of the transgene (Figure 9).  
For characterization of the transgenic models, we took the mortality record, tested 
the motor ability, and examined the neurodegeneration. Life expectancy of patients with 
Parkinson disease is reduced compared with the general population. We found expression 
of either RH-EIF4G1 or AV-EIF4G1 caused premature mortality compared with WT-
EIF4G1 expressing flies. The mean lifespans of RH-EIF4G1 and AV-EIF4G1 transgenic 
flies survived were 54 and 40 days, respectively, while the mean lifespan of WT-EIF4G1 
flies is 62 days. The ages at which 50% of the RH-EIF4G1 and AV-EIF4G1 transgenic flies 
died were 54 and 39 days, respectively, compared with 65 days of WT-EIF4G1 and non-
transgenic control flies (Figure 10). Interestingly, though the R1205H mutation was the 
one that identified in the P30 family, AV mutation caused more reduced life span.  
As PD is typically diagnosed and characterized by motor dysfunctions, we tested 
the locomotion ability of the transgenic flies by climbing assays. We found that at 5-week 
age, the performances of the RH-EIF4G1 and AV-EIF4G1 transgenic flies were 
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significantly worse than WT transgenic and Control flies, though at early age there was no 
difference between the flies expressing mutant EIF4G1 and WT-EIF4G1 (Figure 11). 
Moreover, AV-EIF4G1 flies showed more severe motor defects than RH-EIF4G1 flies 
(Figure 11). 
The most convincing proof that the mutations are causal is the neurodegeneration 
in the flies, as the pathological hallmark of PD is the loss of dopaminergic neurons in the 
substantia nigra. We stained the TH neurons in both young and aged flies, and found at 6-
week age, the TH-positive neurons in PPL1, PPM1/2 clusters of RH-EIF4G1 and AV-
EIF4G1 flies were significantly less than those of WT-EIF4G1 and Control flies (Figure 
13). And there was DAergic neurons loss in PPM3 of AV-EIF4G1 flies compared with WT-
EIF4G1 and Control flies, while there was no significant difference among all the lines 
when they were young (Figure 12).  
Our data suggested overexpression of mutant EIF4G1 in dopaminergic neurons 
could result in neuronal loss, motor function impairment, and early mortality. Several 
questions remained unanswered. First, we have not tested if the neurodegeneration is 
dopaminergic neuron specific. It could be addressed by crossing the UAS lines with either 
dopa decarboxylase (ddc)-GAL4 driver line (Feany and Bender 2000), in which GAL4 is 
expressed in both TH and serotonin (5-HT) neurons, or embryonic lethal abnormal visual 
system (elav)-GAL4 line (Koushika, Lisbin et al. 1996), in which GAL4 expression is pan-
neuronal. But different GAL4 lines have different driver strength, and the expression level 
of the transgene is critical in our case, it will be tricky to adjust the extent of the transgene 
expression. Second, the A502V mutation seemed to cause more severe symptoms than the 
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R1205H mutation. As the two mutations are far from each other in the primary sequence, 
they may have different effects on the protein function. We found one of the functional 
differences of the two mutations in the mechanism studies, and this will be discussed later.  
Generation of EIF4G1 mutations knock-in cell lines for mechanistic study  
As function of eIF4G1 has been well studied in protein translation initiation, and 
numerous studies have suggested the role of translation in neurodegeneration, so to study 
the mechanism of how the mutations of EIF4G1 result in neurodegeneration, we firstly 
wanted to know if the mutations affect protein translation initiation. For in vitro studies, 
we started with transient transfection system. But we hardly saw overexpression of eIF4G1 
in transfected cells while V5 tag immunoblotting confirmed the expression of transfected 
eIF4G1 (Figure 14). We assumed it was because the endogenous eIF4G1 was abundantly 
expressed and the overall eIF4G1 protein amount was highly regulated, it was hard to 
induce strong exogenous eIF4G1 expression. Without knowing how much portion of the 
overall eIF4G1 pool was taken by transfected mutant eIF4G1, it was difficult to dissect the 
role of the mutations. And since cell plating confluency, transfection reagents toxicity, and 
transfection efficiency all have an impact on protein translation, so results of the in vitro 
studies were inconsistent and unreliable. So we pivoted to generating RH-EIF4G1 and AV-
EIF4G1 knock-in cell lines by using the CRISPR/Cas9 system. 
At the time we adopted CRISPR/Cas9 in the lab, the majority of the studies reported 
were making knock-down or knock-out organisms, but generating knock-in systems taking 
advantage of the cellular homology-directed repair mechanism remained inefficient (Wang, 
Yang et al. 2013, Yang, Wang et al. 2013, Platt, Chen et al. 2014, Dow, Fisher et al. 2015). 
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One potential idea was about the nuclease activity of CRISPR/Cas9 is so robust that 
continuous editing could happen until the targeting site is largely altered (Wang, Yang et 
al. 2013, Canver, Bauer et al. 2014, Paquet, Kwart et al. 2016). So for our first design of 
single-guide RNA (sgRNA) and single-stranded DNA oligonucleotides (ssODNs) repair 
template, we considered that if the targeting site overlaps with the mutation site, the 
nucleotide change could potentially block the second cleavage (Figure 15). Though our 
sgRNAs and ssODNs were functional and efficient in HEK cells (Figure 16-29), we did 
not get positive knock-in clones in both RH and AV sgRNAs treated cells (Figure 20, 21). 
By sequencing the clones, we found unwanted indel mutations presented together with 
HDR events (Figure 21). We realized the re-cut occurred at the edited site even though our 
chosen sgRNA targeting sequence overlapped with the intended mutation site. This 
indicated that one nucleotide difference might not be sufficient to block the binding of 
sgRNA with the genomic DNA, so the second or more cleavages continued to happen until 
the NHEJ-mediated modification prevented the further cutting. So in our second design, 
we induced a synonymous mutation at the binding-required NGG protospacer adjacent 
motif (PAM) sequence. And to ensure large scale genotyping, we also designed a silent 
mutation at the repair template to create a restriction enzyme targeting site if the intended 
mutation itself did not present to be a restriction enzyme targeting site (Figure 22). We also 
tried the cell sorting enrichment and NHEJ inhibitor treatment to increase the chance of 
identifying positive knock-in clones (Figure 23). We eventually got the knock-in cell lines 
of both mutations, and sequencing results confirmed both lines were heterozygous (Figure 
24, 25). Through this process, we have optimized the procedure of generating knock-in cell 
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lines using CRISPR-Cas9. We can apply the same protocol to generate knock-in embryonic 
stem cells, which can be differentiated into dopaminergic neurons. 
We used a radioactive 35S-Met/Cys labeling assay to measure the protein synthesis 
in the wild type and mutation knock-in cells. Liquid scintillation reads of the radioactive 
signal in the mutant cells were significantly lower than that in the wild-type cells, 
suggesting a decrease in protein synthesis rate. And SDS-PAGE analysis of the whole cell 
lysate indicated protein synthesis in a large range of molecular size was decreased (Figure 
26). And after feeding the flies with 35S-Met/Cys mixed food, we also detected the 
decreased protein synthesis rate of mutant EIF4G1 flies compared with that of WT-EIF4G1 
transgenic flies (Figure 27). These data suggested that EIF4G1 mutations were either 
dominant negative or affecting subset of transcripts, and potential altered protein synthesis 
was associated with neurodegeneration. This finding was surprising to us, particularly 
because our lab just reported pathogenic G2019S LRRK2 could elevate global protein 
synthesis and cause neurotoxicity. But it was also reported that sustained protein translation 
repression was associated with synaptic failure and neurodegeneration in prion-diseased 
mice. It could be explained that protein homeostasis is crucial for cell survival, either too 
much or too little is detrimental.  
Also, bicistronic reporter assays dissecting cap-dependent and cap-independent 
translation showed both cap-dependent and cap-independent translation were dramatically 
decreased in AV knock-in cells, while slightly reduced cap-dependent translation in RH 
knock-in cells (Figure 28). These finding helped us understand better about AV transgenic 
flies showed more severe symptoms compared with RH transgenic flies. It could due to the 
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dose-dependent effect on cap-dependent translation as well as AV mutation particularly 
affects the cap-independent translation. Though only 10-15% of the total mRNAs are 
translated by the cap-independent manner, which could partially explain the little 
difference about the effect on global translation of RH and AV, these mRNAs are 
particularly translated in the conditions such as cellular stress states, viral infection, and 
diseases. So the hypothesis could be as the flies were aging and accumulating stresses, the 
AV mutation-bearing flies were more vulnerable to the stress conditions, thus they 
developed worse outcomes.  
The next question we want to answer is why the mutations could cause 
dopaminergic neuron specific loss. Though at this stage, we know the mutations reduce 
global translation, we have to study at more granular level to address the specificity 
question. Translation initiation factors seem to function in a general manner, their 
preference for specific mRNAs features under particular conditions has been discovered 
and realized. There were studies about the preference of eIF4G1 on translation initiation of 
mRNA with particular sequence features. It was reported that in breast cancer cell line, 
depletion of eIF4G1 would affect the mRNA with multiple upstream open reading frames 
(Ramirez-Valle, Braunstein et al. 2008). There was also a study about that in C.elegans, 
eIF4G1 mediated somatic maintenance by regulating mRNA with longer-than-average 
ORF length (Rogers, Chen et al. 2011). In a recently published paper, eIF4G1 was 
suggested being required for efficient translation of mRNAs with structured 5’ UTR (Liew, 
Assmann et al. 2014). We hypothesize that the mutations could alter the preference of 
eIF4G1 on particular mRNA sequence features like coding sequence lengths, the presence 
102 
 
of upstream open reading frames (uORF) and upstream start codon (uATG) and secondary 
structures in the 5′ untranslated region (UTR) and so on. So our next steps will be 
employing the genome-wide ribosome-profiling technique to identify the differential 
translated mRNAs due to mutations in EIF4G1 and further analyze the sequence features 
of theses mRNAs in the transgenic fly model and EIF4G1 mutation knock-in SH-SY5Y 
cells and even hES cell-derived DAergic neurons. So we will be able to expand our 
knowledge of the specific genes and signal pathways that lead to Parkinson disease and 
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